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Given the complexity of critical care practice today, it’s
impossible for even experienced clinicians to remember
all the information required to give safe and effective care
to critically ill patients. Clinicians frequently need to use a
variety of clinical resources to verify drug information,
normal laboratory and physiologic values, ECG and he-
modynamic monitoring information, emergency algo-
rithms, and other essential facts of patient management.
To save time and avoid frustration, clinicians often
create their own “pocket guides” by cutting and past-
ing together information from a variety of sources so
they always have a quick reference source available.
The AACN Essentials of Critical Care Nursing Pocket
Handbook is designed to provide busy clinicians with
an easy to use resource that can, literally, be kept in
their pockets. The pocket handbook contains selected
tables and figures from the textbook, AACN Essentials
of Critical Care Nursing, and includes items that clini-
cians are most likely to need at their fingertips:
• Critical care drug tables (common vasoactive drugs,
neuromuscular blocking agents, antiarrhythmics, IV
medication guidelines)
• Normal values table for laboratory tests and physio-
logic parameters
• Lists of assessment components
• Cardiac rhythms: ECG characteristics and treatment
guides including sample rhythm strips
• 12-lead ECG changes in acute myocardial ischemia
and infarct
• Troubleshooting guides for hemodynamic monitoring
equipment
• Indications for mechanical ventilation
• Weaning assessment tool
• Chest x-ray interpretation
We hope this pocket book will, indeed, be placed in your
pocket and assist you in making a difference in the lives
of the patients and families you encounter.
Marianne Chulay
Suzi Burns
Preface
xii
To our critical care nursing colleagues around the world whose wonderful work and efforts 
ensure the safe passage of patients through the critical care environment.
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 1.1 Normal Values Table / 2
NORMAL VALUES
1.1  Normal Values Table
Abbreviation Definition Normal Value Formula
BSA Body surface area Meters squared (m2) Value obtained from a nomogram based on height and weight
C(a  v)O2 Arteriovenous oxygen content 4-6 mL/100 mL C(a  v)O2 (mL/100 mL or vol %)  CaO2  CvO2
difference
CaO2 Arterial oxygen content Will vary with hemoglobin CaO2 (mL O2/100 mL blood or vol %) 
concentration and PaO2 on (Hb  1.39) SaO2  (PaO2  0.0031)
air from 19-20 mL/100 mL
CI Cardiac index 2.5-3.0 L/min/m2 CI (L/min/m2) 
CK Creatinine kinase 150 mcg/L
CK-MB Creatinine kinase MB band 10 ng/mL or 3% of total
CO Cardiac output 4-6 L/min CO  Stroke volume  heart rate
CvO2 Mixed venous oxygen content Will vary with CaO2, cardiac 
output, and O2 consumption
from 14-15 mL/100 mL
CVP Central venous pressure 2-8 mm Hg
dp/dt First time derivative of left 13-14 seconds
ventricular pressure
EDC Effective dynamic compliance 35-45 mL/cm H2O women EDC (mL/cm H2O) 
40-50 mL/cm H2O men
EDV End-diastolic volume 50-90 mL
EF Ejection fraction 70% Ejection fraction 
SV
EDV
tidal volume (mL)
peak airway pressure (cm H2O)
cardiac output (L/min)
body surface area (m2)
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1.1  Normal Values Table (continued )
Abbreviation Definition Normal Value Formula
FRC Functional residual capacity 2400 mL
HR Heart rate 60-90 beats/min
IF Inspiratory force 75-100 cm H2O
LVSW Left ventricular stroke work 8-10 g/m/m2 LVSW  SI  MAP  0.0144
MAP Mean systemic arterial pressure  70 mm Hg Map estimate 
O2 availability Oxygen availability 550-650 mL/min/m
2 O2 availability (mL/min/m
2)  CI  CaO2  10
O2 extraction ratio Oxygen extraction ratio 0.25 O2 extraction ratio 
P(A  a)O2 Alveolar-arterial oxygen gradient 25-65 mm Hg at FiO2  1.0 P(A  a)O2 (mm Hg)  PAO2  PaO2
P(A  a)o2 Mean partial pressure of oxygen 104 mm Hg
in alveolus
P(A  a)co2 Partial pressure of carbon dioxide 40 mm Hg
in alveolus
PacO2 Partial pressure of carbon 35-45 mm Hg
dioxide in arterial blood
PAD Pulmonary artery diastolic 5-12 mm Hg
C(a  v)O2
CaO2
(Systolic  2 Diastolic)
3
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41.1  Normal Values Table (continued )
Abbreviation Definition Normal Value Formula
PaO2 Partial pressure of oxygen in Will vary with patient’s age
arterial blood and the FiO2. On room air: 
80-95 mm Hg. On 100% 
O2: 640 mm Hg
PAS Pulmonary artery 54 systolic 16-24 mm Hg
pressure
PCWP Mean pulmonary capillary wedge 5-12 mm Hg
pressure
PvCO2 Partial pressure of carbon 41-51 mm Hg
dioxide in mixed venous blood
PvO2 Partial pressure of oxygen in Will vary with the FiO2,
mixed venous blood cardiac output, and oxygen 
consumption from 
35-40 mm Hg
PVR Pulmonary vascular resistance 120-200 dynes/s/cm5 PVR 5  (dynes/s/cm5) 
1.5-2.5 mm Hg
QS/QT Right-to-left shunt (percentage 5%-8% QS/QT(%)   100
of cardiac output flowing past
nonventilated alveoli or the Valid only when arterial blood is 100% saturated
equivalent
0.0031  P(A  a)O2
C(a  v)O2  (0.0031  P[A  a]O2)
(PA [mm Hg]  PCWP [mm Hg])  79.9
cardiac output (L/min)
51.1  Normal Values Table (continued )
Abbreviation Definition Normal Value Formula
R or RQ Respiratory quotient 0.8 RQ 
RVSW Right ventricular stroke work 51-61 g/m/m2 RVSW  SI  MPAP  0.0144
SaO2 Percentage of oxyhemoglobin 96%-100% (air)
saturation of arterial blood
SI Stroke index 35-50 mL/m2 SI (mL/min/m2) 
SV Stroke volume 50-100 mL/beat SV (mL/beat) 
SvO2 Percentage of oxyhemoglobin 70-80% (air)
saturation of mixed venous 
blood
SVR Systemic vascular resistance 900-1200 dynes/s/cm5 SVR (TPR) (dynes/s/cm5) 
10-15 mm Hg
(mm Hg  80  dynes/s/cm5)
Troponin I Troponin I 0.4 ng/mL
Troponin T Troponin T 0.1 ng/mL
(MAP [mm Hg]  CVP [mm Hg])  79.9
cardiac output (L/min)
cardiac output (mL)
heart rate
stroke volume
body surface area
VCO2
VO2
61.1  Normal Values Table (continued )
Abbreviation Definition Normal Value Formula
VC Vital capacity 65-75 mL/kg
VCO2 Carbon dioxide production 192 mL/min
VD Dead space 150 mL VD/VT 
VD/VT Dead space to tidal volume ratio 0.25-0.40
VO2 Oxygen consumption 115-165 mL/min/m
2 O2 extraction ratio 
VT Tidal volume 6-8 mL/kg
Adapted from: Hall J, Schmidt G, Wood L. Principles of critical care. 3rd ed. New York: McGraw Hill, 2005; cover tables I-IV.
C(a  v)O2
CaO2
PaCO2  PEco2
Paco2
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ASSESSMENT
82.1  Summary of Prearrival and Admission Quick Check Assessments
Prearrival Assessment
• Abbreviated report on patient (age, gender, chief complaint, diagnosis, 
pertinent history, physiologic status, invasive devices, 
equipment, and status of laboratory/diagnostic tests)
• Complete room setup, including verification of proper 
equipment functioning
Admission Quick Check Assessment
• General appearance (consciousness)
• Airway:
Patency
Position of artificial airway (if present)
• Breathing:
Quantity and quality of respirations (rate, depth, pattern, 
symmetry, effort, use of accessory muscles)
Breath sounds
Presence of spontaneous breathing
• Circulation and Cerebral Perfusion:
ECG (rate, rhythm, and presence of ectopy)
Blood pressure
Peripheral pulses and capillary refill
Skin, color, temperature, moisture
Presence of bleeding
Level of consciousness, responsiveness
• Chief Complaint:
Primary body system
Associated symptoms
• Drugs and Diagnostic Tests:
Drugs prior to admission (prescribed, over-the-counter, illicit)
Current medications
Review diagnostic test results
• Equipment:
Patency of vascular and drainage systems
Appropriate functioning and labeling of all equipment connected to patient
• Allergies
92.2  Summary of Comprehensive Admission Assessment Requirements
Past Medical History
• Medical conditions, surgical procedures
• Psychiatric/emotional problems
• Hospitalizations
• Medications (prescription, over-the-counter, illicit drugs) and 
time of last medication dose
• Allergies
• Review of body systems (see Table 1-7)
Social History
• Age, gender
• Ethnic origin
• Height, weight
• Highest educational level completed
• Occupation
• Marital status
• Primary family members/significant others
• Religious affiliation
• Advance Directive and Durable Power of Attorney for Health Care
• Substance use (alcohol, drugs, caffeine, tobacco)
• Domestic Abuse or Vulnerable Adult Screen
Psychosocial Assessment
• General communication
• Coping styles
• Anxiety and stress
• Expectations of critical care unit
• Current stresses
• Family needs
Spirituality
• Faith/spiritual preference
• Healing practices
Physical Assessment
• Nervous system
• Cardiovascular system
• Respiratory system
• Renal system
• Gastrointestinal system
• Endocrine, hematologic, and immune systems
• Integumentary system
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2.3  Suggested Questions for Review of Past History Categorized by Body System
Body System History Questions
Nervous • Have you ever had a seizure?
• Have you ever fainted, blacked out, or had 
delirium tremens (DTs)?
• Do you ever have numbness, tingling, or 
weakness in any part of your body?
• Do you have any difficulty with your hearing, 
vision,or speech?
• Has your daily activity level changed due to your 
present condition?
• Do you require any assistive devices such 
as canes?
Cardiovascular • Have you experienced any heart problems 
or disease such as heart attacks or strokes?
• Do you have any problems with extreme fatigue?
• Do you have an irregular heart rhythm?
• Do you have high blood pressure?
• Do you have a pacemaker or an implanted 
defibrillator?
Respiratory • Do you ever experience shortness of breath?
• Do you have any pain associated with breathing?
• Do you have a persistent cough? Is it productive?
• Have you had any exposure to environmental 
agents that might affect the lungs?
• Do you have sleep apnea?
Body System History Questions
Renal • Have you had any change in frequency of 
urination?
• Do you have any burning, pain, discharge, 
or difficulty when you urinate?
• Have you had blood in your urine?
Gastrointestinal • Has there been any recent weight loss or gain?
• Have you had any change in appetite?
• Do you have any problems with nausea 
or vomiting?
• How often do you have a bowel movement and 
has there been a change in the normal 
pattern? Do you have blood in your stools?
• Do you have dentures?
• Do you have any food allergies?
Integumentary • Do you have any problems with your skin?
Endocrine • Do you have any problems with bleeding?
Hematologic • Do you have problems with chronic infections?
Immunologic • Have you recently been exposed to a contagious
illness?
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Body System History Questions
Psychosocial • Do you have any physical conditions which make 
communication difficult (hearing loss, visual 
disturbances, language barriers, etc)?
• How do you best learn? Do you need information 
repeated several times and/or require information 
in advance of teaching sessions?
• What are the ways you cope with stress, crises, or pain?
• Who are the important people in your “family” or 
network? Who do you want to make decisions with you, 
or for you?
• Have you had any previous experiences with critical illness?
• Have you ever been abused?
• Have you ever experienced trouble with anxiety, irritability, 
being confused, mood swings, or suicide attempts?
• What are the cultural practices, religious influences, 
and values that are important to the family?
• What are family members’ perceptions and expectations 
of the critical care staff and the setting?
2.3  Suggested Questions for Review of Past History Categorized by Body System (continued )
Body System History Questions
Spiritual • What is your faith or spiritual preference?
• What practices help you heal or deal with
stress?
• Would you like to see a chaplain, priest, 
or other type of healer?
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2.4  Ongoing Assessment Template
Body System Assessment Parameters
Nervous • LOC
• Pupils
• Motor strength of extremities
Cardiovascular • Blood pressure
• Heart rate and rhythm
• Heart sounds
• Capillary refill
• Peripheral pulses
• Patency of IVs
• Verification of IV solutions 
and medications
• Hemodynamic pressures and waveforms
• Cardiac output data
Respiratory • Respiratory rate and rhythm
• Breath sounds
• Color and amount of secretions
• Noninvasive technology information (eg, pulse 
oximetry, end-tidal CO2)
• Mechanical ventilatory parameters
• Arterial and venous blood gases
Renal • Intake and output
• Color and amount of urinary output
• BUN/creatinine values
Body System Assessment Parameters
Gastrointestinal • Bowel sounds
• Contour of abdomen
• Position of drainage tubes
• Color and amount of secretions
• Bilirubin and albumin values
Endocrine, • Fluid balance
hematologic, • Electrolyte and glucose values
and • CBC and coagulation values
immunologic • Temperature
• WBC with differential count
Integumentary • Color and temperature of skin
• Intactness of skin
• Areas of redness
Pain/discomfort • Assessed in each system
• Response to interventions
Psychosocial • Mental status and behavioral responses
• Reaction to critical illness experience 
(eg, stress, anxiety, coping, mood)
• Presence of cognitive impairments (dementia, 
delirium), depression, or demoralization
• Family functioning and needs
• Ability to communicate needs and participate in care
• Sleep patterns
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2.5  Identification of Symptom Characteristics
Characteristic Sample Questions
Onset How and under what circumstances did it begin? Was the onset sudden or gradual? Did it progress?
Location Where is it? Does it stay in the same place or does it radiate or move around?
Frequency How often does it occur?
Quality Is it dull, sharp, burning, throbbing, etc?
Intensity Rank pain on a scale (numeric, word description, FACES, FLACC)
Quantity How long does it last?
Setting What are you doing when it happens?
Associated findings Are there other signs and symptoms that occur when this happens?
Aggravating and What things make it worse? What things make it better
alleviating factors
2.6  Chest Pain Assessment
Ask the Question Examples
P (Provoke) What provokes the pain or what precipitates the pain? Climbing the stairs, walking; or may be unpredictable—comes on at rest
Q (Quality) What is the quality of the pain? Pressure, tightness; may have associated symptoms such as nausea, 
vomiting, diaphoresis
R (Radiation) Does the pain radiate to locations other than the chest? Jaw, neck, scapular area, or left arm
S (Severity) What is the severity of the pain (on a scale of 1-10)? On a scale of 1-10, with 10 being the worst, how bad is your pain?
T (Timing) What is the time of onset of this episode of pain that When did this episode of pain that brought you to the hospital start?
caused you to come to the hospital? Did this episode wax and wane or was it constant?
For how many days, months, or years have you had similar pain?
14
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2.7  Pain Assessment Tools Commonly Used in Critically Ill Patients
Numeric Rating Scales (NRS)
NRS Verbal NRS-101
(0 to 10 scale) (0 to 100 scale)
0  No pain 0  No pain
10  Worst pain imaginable 100  Worst pain imaginable
Verbal Descriptive Scale
None Mild Moderate Severe
Visual Analog Scale
No pain ______________________________________________________________________________________ Worst pain imaginable
16
2.8  CAM-ICU Worksheet
17
2.8  CAM-ICU Worksheet (continued )
Confusion Assessment Method for the intensive care unit (CAM-ICU) worksheet. Delirium is diagnosed
when both I and II are positive, along with either III or IV. (With permission from: E. Wesley Ely, MD, MPH,
Vanderbilt University, Nashville, TN, 2002; complete training manual is available at www.ICUdelirium.org).
18
2.9  Glasgow Coma Scale
Behavior Scorea
Eye Opening (E)
Spontaneous 4
To verbal stimuli 3
To pain 2
None 1
Motor Response (M)
Obeys commands 6
Localizes pain 5
Withdraws to pain 4
Abnormal flexion 3
Extensor response 2
None 1
Verbal Response (V)
Oriented 5
Confused 4
Inappropriate words 3
Incomprehensible sounds 2
None 1
aComa score  E  M  V (scores range 3-15).
 Abnormal motor responses. (A) Decorticate posturing. (B) Decerebrate pos-
turing. (C) Decorticate posturing on right side and decerebrate posturing on left
side of body. (Reprinted from: Carlson BA. Neurologic clinical assessment. In: Ur-
den LD, Stacy KM, Lough ME, eds. Thelan’s Critical Care Nursing: Diagnosis and
Management. St Louis, MO: Mosby; 2002:649.)
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2.10  Sensory Dermatomes.
A
(A) Anterior view. 
20
2.10  Sensory Dermatomes (continued )
B
(B) Posterior view. (Reprinted from: Carlson BA. Neurologic anatomy and physiology. In: Urden LD, Stacy KM, Lough ME, eds.
Thelan’s Critical Care Nursing: Diagnosis and Management. St Louis, MO: Mosby; 2002: 641.)
21
2.11  Edema Rating Scale
Following the application and removal of firm digital pressure against the
tissue, the edema is evaluated for one of the following responses:
• 0 No depression in tissue
• 1 Small depression in tissue, disappearing in 1 second
• 2 Depression in tissue disappears in 1-2 second
• 3 Depression in tissue disappears in 2-3 second
• 4 Depression in tissue disappears in 4 second
2.12  Peripheral Pulse Rating Scale
• 0 Absent pulse
• 1 Palpable but thready; easily obliterated with light pressure
• 2 Normal; cannot obliterate with light pressure
• 3 Full
• 4 Full and bounding
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2.13  Physiologic Effects of Aging
Body System Effects
Nervous Diminished hearing and vision, short-term memory loss, altered motor coordination, decreased muscle tone and strength, 
slower response to verbal and motor stimuli, decreased ability to synthesize new information, increased sensitivity to 
altered temperature states, increased sensitivity to sedation (confusion or agitation), decreased alertness levels
Cardiovascular Increased effects of atherosclerosis of vessels and heart valves, decreased stroke volume with resulting decreased cardiac
output, decreased myocardial compliance, increased workload of heart, diminished peripheral pulses
Respiratory Decreased compliance and elasticity, decreased vital capacity, increased residual volume, less effective cough, decreased
response to hypercapnia
Renal Decreased glomerular filtration rate, increased risk of fluid and electrolyte imbalances
Gastrointestinal Increased presence of dentition problems, decreased intestinal mobility, decreased hepatic metabolism, increased risk of 
altered nutritional states
Endocrine, hematologic, Increased incidence of diabetes, thyroid disorders, and anemia; decreased antibody response and cellular immunity
and immunologic
Integumentary Decreased skin turgor, increased capillary fragility and bruising, decreased elasticity
Miscellaneous Altered pharmacokinetics and pharmacodynamics, decreased range of motion of joints and extremities
Psychosocial Difficulty falling asleep and fragmented sleep patterns, increased incidence of depression and anxiety, cognitive impairment
disorders, difficulty with change
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3.1  ECG Lead Placement for a Three-Wire System
Lead MCL1: ground electrode on the posterior right shoulder, negative elec-
trode on the posterior left shoulder, and positive electrode in the V1 posi-
tion (fourth intercostal space, right of the sternum).
Lead MCL6: ground electrode on the posterior right shoulder, negative elec-
trode on the posterior left shoulder, and positive electrode in the V6 posi-
tion (horizontal from V4 in the midaxillary line).
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3.1  ECG Lead Placement for a Three-Wire System (continued )
Lead III: the positive electrode is placed on the upper left abdomen. Lead II: ground electrode on the left shoulder, negative electrode on right
shoulder, and positive electrode on the left lower rib cage.
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3.2  ECG Lead Placement for a Five-Wire System
(A) Correct electrode placement for using a 5-wire monitoring cable. Right and left arm electrodes are placed on the shoulders and right and left leg electrodes are placed low on the
thorax or on the hips. With the arm and leg electrodes placed as illustrated, leads I, II, III, aVR, aVL, and aVF can be obtained by selecting the desired lead on the bedside monitor. To
obtain lead V1 place the chest lead in the fourth intercostal space at the right sternal border and select “V” on the bedside monitor. To obtain lead V6, place the chest lead in the fifth in-
tercostal space at the left midaxillary line and select “V” on the bedside monitor. (B) Correct lead placement for obtaining MCL1 and MCL6 using a 3-wire lead system. Place the right
arm electrode on the left shoulder; the left arm electrode in the fourth intercostal space at the right sternal border; and the left leg electrode in the fifth intercostal space at the left mi-
daxillary line. To monitor in MCL1, select lead I on the bedside monitor. To monitor in MCL6, select lead II on the bedside monitor. (Adapted from Drew BJ. Bedside electrocardiogram
monitoring. AACN Clin Issues Crit Care Nurs. 1993;4:26, 28.)
A
Angle of
Louis
B
Angle of
Louis
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3.3  Twelve-Lead ECG Placement
(A) Limb electrodes can be placed anywhere on arms and legs. Standard placement is shown here on wrists and ankles.
(B) Chest electrode placement. V1  fourth intercostal space to right of sternum; V2  fourth intercostal space to left of ster-
num; V3  halfway between V2 and V4 in a straight line; V4  fifth intercostal space at midclavicular line; V5  same level
as V4 at anterior axillary line; V6  same level as V4 at midaxillary line.
Angle of Louis
A
B
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3.4  Right Side ECG Chest Lead Placement
V4R
V5R
V6R
A
V7 V8 V9B
(A) Right side chest leads. V4R at right fifth intercostal space, midclavicular line; V5R at right fifth intercostal space, anterior axillary line; V6R at right fifth in-
tercostal space, midaxillary line. (B) Posterior leads: V6 is shown at its normal location at the left fifth intercostal space, midaxillary line; V7 at posterior axil-
lary line; V8 at tip of scapula; V9 next to spine.
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3.5  Waves, Complexes, and Intervals
Atrial
depolarization
AV node
depolarization
Ventricular
depolarization
Ventricular
repolarization
T waveP wave
Lead II
V1
QRS waveIsoelectric
line after
P wave
Electrocardiographic waves, complexes, and intervals in leads II and V1.
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3.6  Heart Rate Determination
(A) Heart rate determination for a regular rhythm using little boxes between two R waves. One RR interval is marked at the
top of the ECG paper. There are 25 little boxes between these two R waves. There are 1500 little boxes in a 60-second strip. By
dividing 1500 by 25, one calculates a heart rate of 60 beats/min. Heart rate can also be determined for a regular rhythm
counting large boxes between R waves. There are five large boxes between R waves. There are 300 large boxes in a 60-second
strip. By dividing 300 by 5, one calculates a heart rate of 60 beats/min. (B) Heart rate determination for a regular or irregular
rhythm using the number of RR intervals in a 6-second strip and multiplying by 10. There are seven RR intervals in this exam-
ple. Multiplying by 10 gives a heart rate of 70 beats/min. (Gilmore SB, Woods SL. Electrocardiography and vectorcardiography.
In: Woods SL, Froelicher ES, Motzer SU, eds. Cardiac Nursing 3rd ed. Philadelphia, PA: JB Lippincott; 1995:295.)
R to R
6 seconds
3 seconds3 seconds
A
B
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3.7  Heart Rate Determination Using the Electrocardiogram Large Boxes
Number of Large Boxes Between R Waves Heart Rate (Beats/Min)
1 300
2 150
3 100
4 75
5 60
6 50
7 40
8 38
9 33
10 30
3.8  Recommended Leads for Continuous ECG Monitoring
Purpose Best Leads
Arrhythmia detection V1 (V6 next best)
RCA ischemia, inferior MI III, aVF
LAD ischemia, anterior MI V3
Circumflex ischemia, lateral MI I, aVL (III, aVF best limb leads)
RV infarction V4R
Axis shifts I and aVF together
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3.9  Advantages of Common Monitoring Leads
Lead Advantages
Preferred Monitoring Leads
V1 and V6 (or MCL1 and MCL6 Differentiate between right and left bundle branch block
if using a 3-wire system) Morphology clues to differentiate between ventricular beats and supraventricular beats with
aberrant conduction
Differentiate between right and left ventricular ectopy
Differentiate between right and left ventricular pacing
Usually shows well-formed P waves
Placement of electrodes keeps apex clear for auscultation or defibrillation
Other Monitoring Leads
Lead II Usually shows well-formed P waves
Often best lead for identification of atrial flutter waves
Usually has tall, upright QRS complex on which to synchronize machine for cardioversion
Allows identification of retrograde P waves
Lead III or aVF Assists in diagnosis of hemiblock
Allows identification of retrograde P waves
Allows Identification of atrial flutter waves
Best limb leads for ST-segment monitoring
Lewis Lead (negative electrode at Often best lead to identify P waves
second right intercostal space,
positive electrode at fourth
right intercostal space)
3.10  Evidence-Based Practice: Bedside Cardiac Monitoring for Arrhythmia Detection
Electrode Application
• Make sure skin is clean and dry before applying
monitoring electrodes.
• Place arm electrodes on shoulder (front, top, or
back) as close as possible to where arm joins
torso.
• Place leg electrodes below the rib cage or on hips.
• Place V1 electrode at the fourth intercostal space
at right sternal border.
• Place V6 electrode at the fifth intercostal space at
left midaxillary line.
• Replace electrodes every 48 hours or more often if
skin irritation occurs.
• Mark electrode position with indelible ink to
ensure consistent lead placement.
Lead Selection
• Use lead V1 as the primary arrhythmia monitoring
lead whenever possible.
• Use lead V6 if lead V1 is not available.
• If using a 3-wire system, use MCL1 as the primary
lead and MCL6 as the second choice lead.
Compiled from Jacobson (2010); Drew, Califf, Funk, et al (2004); and the American Association of Critical-Care Nurse (2004).
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Alarm Limits
• Set heart rate alarms as appropriate for patient’s current heart rate and clinical condition.
• Never turn heart rate alarms off while patient’s rhythm is being monitored.
• Set alarm limits on other parameters if using a computerized arrhythmia monitoring system.
Documentation
• Document the monitoring lead on every rhythm strip.
• Document heart rate, PR interval, QRS width, QT interval with every shift and with any
significant rhythm change.
• Document rhythm strip with every significant rhythm change:
– Onset and termination of tachycardias.
– Symptomatic bradycardias or tachycardias.
– Conversion into or out of atrial flutter or atrial fibrillation.
– All rhythms requiring immediate treatment.
• Place rhythm strips flat on page (avoid folding or winding strips into chart).
Transporting Monitored Patients
• Continue cardiac monitoring using a portable, battery-operated monitor-defibrillator if patient
is required to leave a monitored unit for diagnostic or therapeutic procedures.
• Monitored patients must be accompanied by a health-care provider skilled in ECG
interpretation and defibrillation during transport.
363.11  Evidence-Based Practice: ST-Segment Monitoring
Patient Selection
Class I: ST-segment monitoring recommended for the following
types of patients:
• Patients in the early phase of acute coronary syndromes
(unstable angina, “rule-out MI, ST elevation MI, non–ST-
elevation MI).a,c
• Patients presenting to emergency department with chest pain
or anginal equivalent symptoms.a,c
• Patients and who have undergone nonurgent percutaneous
coronary intervention who have suboptimal angiographic
results.a,c
• Patients with possible variant angina due to coronary
vasospasm.a,c
Class II: ST-segment monitoring may be of benefit in some
patients but is not considered essential for all:
• Patients with post-acute MI (after 24–48 h).a
• Patients who have undergone nonurgent, uncomplicated
percutaneous coronary intervention 1.
• Patients at high risk for ischemia after cardiac or noncardiac
surgery.a
• Pediatric patients at risk of ischemia or infarction due to
congenital or acquired conditions.a
Electrode Application
• Make sure skin is clean and dry before applying monitoring
electrodes.a,b,c
• Place electrodes according to manufacturer recommendations
when using a derived 12-lead ECG system.a
Data compiled from aDrew (2004); bJacobson (2007); and cAACN (2004).
• When using a 3- or 5-wire-monitoring system, place electrodes as follows:
– Place arm electrodes in infraclavicular fossa close to shouldera or on top or back
of shoulder as close to where arm joins torso as possible.
– Place leg electrodes at lowest point on rib cage or on hips.a,b
– Place V1 electrode at the fourth intercostal space at right sternal border.
b
– Place V6 electrode at the fifth intercostal space at left midaxillary line.
b
• Mark electrode placement with indelible ink.a,c
• Replace electrodes every 48 hours or more often if skin irritation occurs.b
Lead Selection
• Monitor all 12 leads continuously if using a 12-lead monitoring system.b
• Use V1 (or V6 if V1 is not possible due to dressings, etc.) for arrhythmia monitoring
in all multilead combinations.b
• Choose the ST-segment monitoring lead according to the patient’s “ischemic
fingerprint” obtained during an ischemic event whenever possible.b,c Use the lead
with the largest ST-segment deviation (elevation or depression).b
• If no ischemic fingerprint is available, use either lead IIIb,c or aVF (whichever has
tallest QRS complex)b for ST-segment monitoring.
• Lead V3 is the best lead for detecting anterior wall ST-segment deviation,
c but can
only be used if the chest lead is not being used for arrhythmia monitoring in lead V1.
Alarm Limits
• Establish baseline ST level with patient in the supine position.a,c
• Set ST alarm parameters at 1 mm above and below the patient’s baseline ST level
in patients at high risk for ischemia.a
• Set ST alarm parameters at 2 mm above and below the patient’s baseline ST level
in more stable patients.a
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3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide
Rhythm ECG Characteristics Treatment
Normal sinus • Rate: 60-100 beats/min. • None.
rhythm (NSR) • Rhythm: Regular.
• P waves: Precede every QRS; consistent shape.
• PR interval: 0.12-0.20 second.
• QRS complex: 0.04-0.10 second.
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Sinus bradycardia • Rate: 60 beats/min. • Treat only if symptomatic.
• Rhythm: Regular. • Atropine 0.5 mg IV.
• P waves: Precede every QRS; consistent shape.
• PR interval: Usually normal (0.12-0.20 second).
• QRS complex: Usually normal (0.04-0.10 second).
• Conduction: Normal through atria, AV node, bundle branches, and ventricles.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
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Sinus tachycardia • Rate: 100 beats/min. • Treat underlying cause.
• Rhythm: Regular.
• P waves: Precede every QRS; consistent shape.
• PR interval: Usually normal (0.12-0.20 second); may be difficult to measure if P waves
are buried in T waves.
• QRS complex: Usually normal (0.04-0.10 second).
• Conduction: Normal through atria, AV node, bundle branches, and ventricles.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
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Sinus arrhythmia • Rate: 60-100 beats/min. • Treatment is usually not required.
• Rhythm: Irregular; phasic increase and decrease in rate, which may or may not be • Hold digoxin if due to digitalis
related to respiration. toxicity.
• P waves: Precede every QRS; consistent shape.
• PR interval: Usually normal.
• QRS complex: Usually normal.
• Conduction: Normal through atria, AV node, bundle branches, and ventricles.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
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Sinus arrest • Rate: Usually within normal range, but may be in the bradycardia range. • Treat underlying cause.
• Rhythm: Irregular due to absence of sinus node discharge. • Discontinue drugs that may be
• P waves: Present when sinus node is firing and absent during periods of sinus arrest. causative.
When present, they precede every QRS complex and are consistent in shape. • Minimize vagal stimulation.
• PR interval: Usually normal when P waves are present. • For frequent sinus arrest
• QRS complex: Usually normal when sinus node is functioning and absent during causing hemodynamic
periods of sinus arrest, unless escape beats occur. compromise, atropine
• Conduction: Normal through atria, AV node, bundle branches, and ventricles when 0.5 mg IV may increase
sinus node is firing. When the sinus node fails to form impulses, there is no heart rate.
conduction through the atria. • Pacemaker may be necessary
for refractory cases.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
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Premature atrial • Rate: Usually within normal range. • Treatment is usually not 
contraction • Rhythm: Usually regular except when PACs occur, resulting in early beats. PACs necessary.
usually have a noncompensatory pause. • Treat underlying cause.
• P waves: Precede every QRS. The configuration of the premature P wave differs from • Drugs (eg, beta-blockers,
that of the sinus P waves. calcium channel blockers,
• PR interval: May be normal or long depending on the prematurity of the beat. Very early procainamide) can be used
PACs may find the AV junction still partially refractory and unable to conduct at a normal if necessary.
rate, resulting in a prolonged PR interval.
• QRS complex: May be normal, aberrant (wide), or absent, depending on the prematurity
of the beat.
• Conduction: PACs travel through the atria differently from sinus impulses because they
originate from a different spot. Conduction through the AV node, bundle branches, and
ventricles is usually normal unless the PAC is very early.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
PACs conducted abnormally in the ventricle.PACs conducted normally in the ventricle.
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Wandering atrial • Rate: 60-100 beats/min. If the rate is faster than 100 beats/min, it is called • Treatment is usually not
pacemaker multifocal atrial tachycardia (MAT). necessary.
• Rhythm: May be slightly irregular. • Treat underlying cause.
• P waves: Varying shapes (upright, flat, inverted, notched) as impulses originate • For symptoms from slow rate,
in different parts of the atria or junction. At least three different P-wave shapes use atropine.
should be seen. • Antiarrhythmic therapy is often
• PR interval: May vary depending on proximity of the pacemaker to the AV node. ineffective, but beta-blockers,
• QRS complex: Usually normal. verapamil, flecainide, 
• Conduction: Conduction through the atria varies as they are depolarized from different amiodarone, or magnesium
spots. Conduction through the bundle branches and ventricles is usually normal. may be successful.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
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Atrial tachycardia • Rate: Atrial rate is 120-250 beats/min. • Eliminate underlying cause and
• Rhythm: Regular unless there is variable block at the AV node. decrease ventricular rate.
• P waves: Differ in shape from sinus P waves because they are ectopic. Precede each • Sedation.
QRS complex but may be hidden in preceding T wave. When block is present, more • Vagal stimulation.
than one P wave appears before each QRS complex. • Digitalis (unless it is the cause 
• PR interval: May be shorter than normal but often difficult to measure because of atrial tachycardia with block).
of hidden P waves. • Propranolol, verapamil, or 
• QRS complex: Usually normal but may be wide if aberrant conduction is present. diltiazem can slow ventricular 
• Conduction: Usually normal through the AV node and into the ventricles. In atrial rate. 
tachycardia with block some atrial impulses do not conduct into the ventricles. • Procainamide, flecainide,
Aberrant ventricular conduction may occur if atrial impulses are conducted into the amiodarone may be effective to
ventricles while the ventricles are still partially refractory. prevent recurrences.
• Radiofrequency ablation is often
successful.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
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Atrial flutter • Rate: Atrial rate varies between 250 and 350 beats/min, most commonly 300. • Treatment depends on
Ventricular rate varies depending on the amount of block at the AV node. hemodynamic consequences 
• Rhythm: Atrial rhythm is regular. Ventricular rhythm may be regular or irregular of arrhythmia.
due to varying AV block. • Cardioversion is preferred 
• P waves: F waves (flutter waves) are seen, characterized by a very regular, for markedly reduced cardiac
“sawtooth” pattern. One F wave is usually hidden in the QRS complex, and when output.
2:1 conduction occurs, F waves may not be readily apparent. • Beta-blockers, calcium channel
• FR interval (flutter wave to the beginning of the QRS complex): May be consistent blockers are used to slow 
or may vary. ventricular rate.
• QRS complex: Usually normal; aberration can occur. • Procainamide, flecainide,
• Conduction: Usually normal through the AV node and ventricles. amiodarone, ibutilide, dofetilide,
sotalol may convert to sinus.
• Use drugs that slow atrial rate
(procainamide, flecainide,
propafenone) only after prior
treatment to ensure AV block
(eg, beta-blockers, calcium
channel blockers).
• Radiofrequency ablation is
usually successful.
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Atrial fibrillation • Rate: Atrial rate is 400-600 beats/min or faster. Ventricular rate varies depending • Eliminate underlying cause.
on the amount of block at the AV node. In new atrial fibrillation, the ventricular • Cardiovert if hemodynamically 
response is usually quite rapid, 160-200 beats/min; in treated atrial fibrillation, unstable.
the ventricular rate is controlled in the normal range of 60-100 beats/min. • Calcium channel blockers and
• Rhythm: Irregular. One of the distinguishing features of atrial fibrillation is the marked beta-blockers are used to slow
irregularity of the ventricular response. ventricular rate. Procainamide, 
• P waves: Not present. Atrial activity is chaotic with no formed atrial impulses visible. disopyramid, flecainide,
Irregular F waves are often seen and vary in size from coarse to very fine. propafenone, amiodarone,
• PR interval: Not measurable; there are no P waves. sotalol, ibutilide, dofetilide
• QRS complex: Usually normal; aberration is common. are used to convert to sinus.
• Conduction: Conduction within the atria is disorganized and follows a very irregular • Radiofrequency ablation may be
pattern. Most of the atrial impulses are blocked within the AV junction. Those impulses successful.
that are conducted through the AV junction are usually conducted normally through the
ventricles. If an atrial impulse reaches the bundle branch system during its refractory
period, aberrant intraventricular conduction can occur.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
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Premature junctional • Rate: 60-100 beats/min or whatever the rate of the basic rhythm. • Treatment is usually not 
complexes • Rhythm: Regular except for occurrence of premature beats. necessary.
• P waves: May occur before, during, or after the QRS complex of the premature beat
and are usually inverted.
• PR interval: Short, usually 0.10 second or less, when P waves precede the QRS.
• QRS complex: Usually normal but may be aberrant if the PJC occurs very early and
conducts into the ventricles during the refractory period of a bundle branch.
• Conduction: Retrograde through the atria; usually normal through the ventricles.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
↑ 
PJC
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Junctional rhythm • Rate: Junctional rhythm, 40-60 beats/min; accelerated junctional rhythm, • Treatment is rarely needed 
60-100 beats/min; junctional tachycardia, 100-250 beats/min. unless rate is too slow or too
• Rhythm: Regular. fast to maintain adequate CO.
• P waves: May precede or follow QRS. • Atropine is used to increase 
• PR interval: Short, 0.11 second or less if P waves precede QRS. rate.
• QRS complex: Usually normal. • Verapamil, propranolol, or
• Conduction: Retrograde through the atria; normal through the ventricles. beta-blockers is used to decrease 
. rate.
• Withhold digitalis if digitalis
toxicity is suspected.
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Premature ventricular • Rate: 60-100 beats/min or the rate of the basic rhythm. • Eliminate underlying cause.
complexes • Rhythm: Irregular because of the early beats. • Drug therapy is not usually
• P waves: Not related to the PVCs. Sinus rhythm is usually not interrupted by the used, but, if desired, lidocaine,
premature beats, so sinus P waves can often be seen occurring regularly amiodarone, procainamide,
throughout the rhythm. beta-blockers may be effective.
• PR interval: Not present before most PVCs. If a P wave happens, by coincidence, 
to precede a PVC, the PR interval is short.
• QRS complex: Wide and bizarre;  0.10 second in duration. May vary in
morphology (size, shape) if they originate from more than one focus in the ventricles.
• Conduction: Wide QRS complexes. Some PVCs may conduct retrograde into the atria,
resulting in inverted P waves following the PVC.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
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Ventricular rhythm • Rate: 50 beats/min for ventricular rhythm and 50-100 beats/min for accelerated • For ventricular escape rhythms,
ventricular rhythm. use atropine to increase sinus
• Rhythm: Usually regular. rate and overdrive ventricular
• P waves: May be seen but at a slower rate than the ventricular focus, with dissociation rhythm.
from the QRS. • Use ventricular pacing
• PR interval: Not measured. to increase ventricular rate
• QRS complex: Wide and bizarre. if escape rhythm is too slow.
• Conduction: If sinus rhythm is the basic rhythm, atrial conduction is normal.
Impulses originating in the ventricles conduct via muscle cell-to-cell conduction,
resulting in the wide QRS complex.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
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Ventricular • Rate: Ventricular rate is faster than 100 beats/min. • Treatment depends on how
tachycardia • Rhythm: Usually regular but may be slightly irregular. rhythm is tolerated.
• P waves: P waves may be seen but will not be related to QRS complexes (dissociated • Lidocaine, amiodarone,
from QRS complexes). If sinus rhythm is the underlying basic rhythm, regular P waves or magnesium should 
are often buried within QRS complexes. be given if patient is
• PR interval: Not measurable because of dissociation of P waves from QRS complexes. stable.
• QRS complex: Wide and bizarre; 0.10 second in duration. • Cardioversion is preferred
• Conduction: Impulse originates in one ventricle and spreads via muscle cell-to-cell for hemodynamic instability.
conduction through both ventricles. There may be retrograde conduction through the • Defibrillation should be 
atria, but more often the sinus node continues to fire regularly and depolarize the atria performed if VT is pulseless.
normally.
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Ventricular • Rate: Rapid, uncoordinated, ineffective. • Immediate defibrillation.
fibrillation • Rhythm: Chaotic, irregular. • CPR required until defibrillator 
• P waves: None seen. is available.
• PR interval: None. • Amiodarone, lidocaine,
• QRS complex: No formed QRS complexes seen; rapid, irregular undulations without magnesium are commonly
any specific pattern. used.
• Conduction: Multiple ectopic foci firing simultaneously in ventricles and depolarizing • After conversion, use
them irregularly and without any organized pattern. Ventricles are not contracting. IV antiarrhythmic that facilitates
conversion to prevent
recurrence.
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Ventricular • Rate: None. • Provide immediate CPR.
asystole • Rhythm: None. • Give IV epinephrine.
• P waves: May be present if the sinus node is functioning. • Give atropine.
• PR interval: None. • Identify and treat cause.
• QRS complex: None.
• Conduction: Atrial conduction may be normal if the sinus node is functioning.
There is no conduction into the ventricles.
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First-degree AV • Rate: Can occur at any sinus rate, usually 60-100 beats/min. • Treatment is usually not
block • Rhythm: Regular. necessary.
• P waves: Normal; precede every QRS.
• PR interval: Prolonged above 0.20 second.
• QRS complex: Usually normal.
• Conduction: Normal through the atria, usually delayed through the AV node. 
Ventricular conduction is normal.
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Second-degree AV • Rate: Can occur at any sinus or atrial rate. • Treatment depends on
block type I • Rhythm: Irregular. Overall appearance of the rhythm demonstrates “group beating.” conduction ratio, ventricular
(Wenckebach; • P waves: Normal. Some P waves are not conducted to the ventricles, but only one rate, and symptoms.
at a time fails to conduct to the ventricle. • Atropine is used for slow 
(Mobitz I) • PR interval: Gradually lengthens in consecutive beats. The PR interval preceding the ventricular rate.
pause is longer than that following the pause • No treatment is given with 
• QRS complex: Usually normal unless there is associated bundle branch block. normal ventricular rate.
• Conduction: Normal through the atria, progressively delayed through the AV node • Discontinue digitalis, beta-
until an impulse fails. Conduction ratios can vary, with ratios as low as 2:1 (every blockers, and calcium channel
other P wave is blocked), up to high ratios such as 15:14 (every 15th P wave blockers.
blocked). • Temporary pacemaker may be
needed for slow ventricular rate.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
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Second-degree AV • Rate: Can occur at any basic rate. • Pacemaker is often needed.
block type II • Rhythm: Irregular due to blocked beats. • Atropine is not recommended.
(Mobitz II) • P waves: Usually regular and precede each QRS. Periodically a P wave is not 
followed by a QRS complex.
• PR interval: Constant before conducted beats. The PR interval preceding the pause 
is the same as that following the pause.
• QRS complex: Usually wide due to associated bundle branch block.
• Conduction: Normal through the atria and through the AV node but intermittently 
blocked in the bundle branch system and fails to reach the ventricles. Conduction 
through the ventricles is abnormally slow due to associated bundle branch block. 
Conduction ratios can vary from 2:1 to only occasional blocked beats.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
57
High-Grade (Advanced) • Rate: Atrial rate <135 beats/min. • Treatment is necessary if patient
High AV block • Rhythm: Regular or irregular, depending on conduction pattern. is symptomatic.
• P waves: Normal; present before every conducted QRS, but two or more • Atropine may increase
consecutive P waves may not be followed by QRS complexes. ventricular rate.
• PR interval: Constant before conducted beats; may be normal or prolonged. • Pacemaker is often required.
• QRS complex: Usually normal in type I and wide in type II advanced blocks.
• Conduction: Normal through the atria. Two or more consecutive atrial impulses fail 
to conduct to the ventricles. Ventricular conduction is normal in type I and 
abnormally slow in type II advanced blocks.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
58
Third-degree AV • Rate: Atrial rate is usually normal; ventricular rate is 45 beats/min. • Pacemaker.
block (complete) • Rhythm: Regular. • Atropine is usually not effective.
• P waves: Normal but dissociated from QRS complexes. • With severely decreased cardiac
• PR interval: No consistent PR intervals because there is no relationship between output, perform CPR until
P waves and QRS complexes. pacemaker available.
• QRS complex: Normal if ventricles controlled by a junctional rhythm; wide if
controlled by a ventricular rhythm.
• Conduction: Normal through the atria. All impulses are blocked at the AV node or in 
the bundle branches, so there is no conduction to the ventricles. Conduction through 
the ventricles is normal if a junctional escape rhythm occurs, and abnormally slow 
if a ventricular escape rhythm occurs.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
59
Ventricular paced • Rate: Depends on type of pacemaker. • None.
rhythm with • Rhythm: Regular.
capture • P waves: Absent or present but dissociated from QRS complexes.
• PR interval: None.
• QRS complex: Pacemaker spike followed immediately by wide, bizarre QRS complex.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
60
Ventricular paced • Conduction: Abnormal. • If hemodynamically stable,
rhythm without • ECG characteristics depend on nature of intrinsic rhythm. elective correction/replacement
capture • Pacemaker spike has no fixed relationship to QRS complexes. of pacemaker.
• If hemodynamically unstable, 
treatment as for third-degree AV 
block.
3.12  Cardiac Rhythms, ECG Characteristics, and Treatment Guide (continued )
Rhythm ECG Characteristics Treatment
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3.13  Guidelines for Management of Atrial Fibrillation and Atrial Flutter (Class I
Recommendations Only)
Pharmacologic Heart Rate Control During Atrial Fibrillation
1. Control of heart rate using either a beta-blocker or nondihydropyridine CCB (in most cases) for patients with persistent or permanent AF (Level B).
2. Administration of AV nodal blocking agents is recommended to achieve heart rate control in patients who develop postoperative AF (Level B).
3. In the absence of preexcitation, IV administration of beta-blockers (esmolol, metoprolol, or propranolol) or nondihydropyridine CCBs (verapamil,
diltiazem) to slow ventricular response to AF in the acute setting, exercising caution in patients with hypotension or HF (Level B).
4. IV administration of digoxin or amiodarone to control heart rate in patients with AF and HF who do not have an accessory pathway (Level B).
5. Oral digoxin is effective to control heart rate at rest and is indicated for patients with HF, LV dysfunction, or for sedentary individuals (Level C).
6. In IV amiodarone is recommended to slow a rapid ventricular response to AF and improve LV function in patients with acute MI (Level C).
7. IV beta-blockers and nondihydropyridine CCBs are recommended to slow a rapid ventricular response to AF in patients with acute MI who do not have
clinical LV dysfunction, bronchospasm, or AV block (Level C).
Preventing Thromboembolism
1. Antithrombotic therapy is recommended for all patients with AF except those with lone AF or contraindications (Level A).
2. For patients without mechanical heart valves at high risk of stroke (prior stroke, TIA, or systemic embolism; rheumatic mitral stenosis), chronic oral
anticoagulant therapy with a vitamin K antagonist is recommended in a dose to achieve the target INR of 2.0 to 3.0 unless contraindicated (Level A).
3. Anticoagulation with a vitamin K antagonist is recommended for patients with more than one moderate risk factor (age 	75, hypertension, HF, LVEF
35%, diabetes) (Level A).
4. INR should be determined at least weekly during initiation of therapy and monthly when anticoagulation is stable (Level A).
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3.13  Guidelines for Management of Atrial Fibrillation and Atrial Flutter (Class I Recommendations Only) (continued )
Preventing Thromboembolism
5. Aspirin 325 mg daily is an alternative to vitamin K antagonists in low-risk patients or those with contraindications to anticoagulation (Level A).
6. For patients with mechanical heart valves, the target intensity of anticoagulation should be based on the type of prosthesis, maintaining an INR of at least
2.5 (Level B).
7. For patients with AF of 	48 hours duration, or when the duration is unknown, anticoagulation (INR: 2.0-3.0) is recommended for at least 3 weeks prior
to and 4 weeks after cardioversion (electrical or pharmacologic) (Level B).
8. For patients with AF of 48 hours duration requiring immediate cardioversion, heparin should be administered concurrently (unless contraindicated) by
an initial IV bolus followed by a continuous infusion in a dose adjusted to prolong the aPTT to 1.5 to 2 times the reference control value. Oral
anticoagulation (INR: 2.0-3.0) should be given for at least 4 weeks after cardioversion. Limited data support SQ administration of LMWH in this category
of patient condition (Level C).
9. For patients with AF of 48 hours duration and hemodynamic instability (angina, MI, shock, or pulmonary edema), cardioversion should be performed
immediately without delay for prior anticoagulation (Level C).
Cardioversion of Atrial Fibrillation
1. Administration of flecainide, dofetilide, propafenone, or ibutilide is recommended for pharmacologic cardioversion (Level A).
2. Immediate electrical (direct-current) cardioversion is recommended for patients with AF involving preexcitation when very rapid tachycardia 
or hemodynamic instability occurs (Level B).
3. When a rapid ventricular response does not respond promptly to pharmacologic measures in patients with myocardial ischemia, symptomatic
hypotension, angina, or HF, immediate R-wave-synchronized cardioversion is recommended (Level C).
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3.13  Guidelines for Management of Atrial Fibrillation and Atrial Flutter (Class I Recommendations Only) (continued )
Cardioversion of Atrial Fibrillation
4. Electrical cardioversion is recommended in patients without hemodynamic instability when symptoms of AF are unacceptable to the patient. In case of
early relapse of AF after cardioversion, repeated electrical cardioversion attempts may be made following administration of antiarrhythmic medication
(Level C).
5. Electrical cardioversion is recommended for patients with acute MI and severe hemodynamic compromise, intractable ischemia, or inadequate rate
control with drugs (Level C).
There are no Class I recommendations for pharmacologic conversion of atrial fibrillation.
Maintenance of Sinus Rhythm
1. An oral beta-blocker to prevent postoperative AF is recommended for patients undergoing cardiac surgery (unless contraindicated) (Level A).
2. Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of AF is recommended (Level C).
Level of Evidence Definitions:
Level A: Data derived from multiple randomized clinical trials or meta-analyses.
Level B: Data derived from a single randomized trial or nonrandomized studies.
Level C: Only consensus opinion of experts, case studies, or standard of care.
Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: ex-
ecutive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of
Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Cir-
culation. 2006;114:700-752.
Abbreviations: AF, atrial fibrillation; aPTT, activated partial thromboplastin time; CCB, calcium channel blocker; HF, heart failure; INR, international normalized ra-
tio; LMWH, low molecular weight heparin; LV, left ventricular; MI, myocardial infarction; TIA, transient ischemic attack.
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3.14  Guidelines for Management of Supraventricular Arrhythmias (Class I
Recommendations Only)
Acute Management of Hemodynamically Stable and Regular Tachycardia
Narrow QRS (SVT) and SVT with BBB:
1. Vagal maneuvers (Valsalva, CSM) (Level B)
2. Adenosine (Level A)
3. Verapamil, diltiazem (Level A)
Preexcited SVT/AF:
1. Flecainide (Level B)
2. Ibutilide (Level B)
3. Procainamide (Level B)
4. Electrical cardioversion (Level C)
Wide QRS Tachycardia of Unknown Origin:
1. Procainamide (Level B)
2. Sotalol (Level B)
3. Amiodarone (Level B)
4. Electrical cardioversion (Level B)
Wide QRS Tachycardia of Unknown Origin in Patients with Poor LV Function:
1. Amiodarone (Level B)
2. Lidocaine (Level B)
3. Electrical cardioversion (Level B)
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3.14  Guidelines for Management of Supraventricular Arrhythmias (Class I Recommendations Only) (continued )
Long-Term Treatment of Recurrent AVNRT
1. Catheter ablation (Level B)
2. Verapamil for recurrent symptomatic AVNRT (Level B)
3. Diltiazem or beta-blockers for recurrent symptomatic AVNRT (Level C)
Infrequent, Well Tolerated Episodes of AVNRT:
1. Vagal maneuvers (Level B)
2. Pill-in-the-pocket (single-dose oral diltiazem plus propranolol) (Level B)
3. Verapamil, diltiazem, beta-blockers, catheter ablation (Level B)
Focal and Nonparoxysmal Junctional Tachycardia Syndromes
Nonparoxysmal Junctional Tachycardia:
1. Reverse digitalis toxicity (Level C)
2. Correct hypokalemia (Level C)
3. Treat myocardial ischemia (Level C)
Long-Term Therapy of Accessory Pathway–Mediated Arrhythmias
1. Catheter ablation for WPW syndrome (preexcitation and symptomatic arrhythmias) that are well tolerated; or with AF and rapid conduction or poorly
tolerated CMT (Level B)
2. Vagal maneuvers for single or infrequent episodes (Level B)
3. Pill-in-the-pocket (verapamil, diltiazem, beta-blockers) for single or infrequent episodes (Level B)
Contraindicated: Verapamil, diltiazem, digoxin
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3.14  Guidelines for Management of Supraventricular Arrhythmias (Class I Recommendations Only) (continued )
Treatment of Focal Atrial Tachycardia
Acute Treatment:
1. Electrical cardioversion if hemodynamically unstable (Level B)
2. Beta-blockers, verapamil, diltiazem for rate control (in absence of digitalis therapy) (Level C)
Prophylactic Therapy:
1. Catheter ablation for recurrent symptomatic or incessant AT (Level B)
2. Beta blockers, verapamil, diltiazem (Level C)
Level of Evidence Definitions:
Level A: Data derived from multiple randomized clinical trials or meta-analyses
Level B: Data derived from a single randomized trial or nonrandomized studies
Level C: Only consensus opinion of experts, case studies, or standard-of-care
Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC Guidelines for the Management of Patients with Supraventricular Arrhythmias–exec-
utive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of
Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias).
Circulation. 2003: 108: 1871-1909.
Abbreviations: AF, atrial fibrillation; AVNRT, atrioventricular nodal reentry tachycardia; BBB, bundle branch block; CMT, circus movement tachycardia; LV,
left ventricular; SVT, supraventricular tachycardia; WPW, Wolff-Parkinson-White.
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3.15  Guidelines for Management of Ventricular Arrhythmias 
(Class I Recommendations Only)
Sustained Monomorphic Ventricular Tachycardia
1. Wide QRS tachycardia should be presumed to be VT if the diagnosis is unclear. (Level C)
2. Electrical cardioversion with sedation is recommended with hemodynamically unstable sustained monomorphic VT (Level C).
Contraindicated: Calcium channel blockers (verapamil, diltiazem) should not be used to terminate wide QRS tachycardia of unknown origin, especially with
history of myocardial dysfunction. 
Polymorphic Ventricular Tachycardia
1. Electrical cardioversion with sedation is recommended for sustained PVT with hemodynamic compromise (Level B).
2. IV beta-blockers are useful if ischemia is suspected or cannot be excluded (Level B).
3. IV amiodarone is useful for recurrent PVT in the absence of QT prolongation (congenital or acquired) (Level C).
4. Urgent angiography and revascularization should be considered with PVT when myocardial ischemia cannot be excluded (Level C).
Torsades de Pointes
1. Withdrawal of any offending drugs and correction of electrolyte abnormalities are recommended for TdP (Level A).
2. Acute and long-term pacing is recommended for TdP due to heart block and symptomatic bradycardia (Level A).
Incessant Ventricular Tachycardia
1. Revascularization and beta blockade followed by IV antiarrhythmic drugs such as procainamide or amiodarone are recommended for recurrent or
incessant PVT (Level B).
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3.15  Guidelines for Management of Ventricular Arrhythmias (Class I Recommendations Only) (continued )
Level of Evidence Definitions:
Level A: Data derived from multiple randomized clinical trials or meta-analyses.
Level B: Data derived from a single randomized trial or nonrandomized studies.
Level C: Only consensus opinion of experts, case studies, or standard of care.
Zipes DP, Camm JA, Borggrefe M., Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Ar-
rhythmias and the Prevention of Sudden Cardiac Death: executive summary: a report of the American College of Cardiology/American Heart Association Task
Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of
Patients with Atrial Fibrillation). Circulation. 2006;114:1088-1132.
Abbreviations PVT, polymorphic ventricular tachycardia; TdP, torsades de pointes; VT, ventricular tachycardia. 
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3.16  Normal 12-Lead ECG Waves
(A) Normal sequence of depolarization through the heart as recorded by
each of the frontal plane leads.
(B) Cross-section of the thorax illustrating how the six precordial leads
record normal electrical activity in the ventricles. The small arrow (1) shows
the initial direction of depolarization through the septum, followed by the di-
rection of ventricular depolarization, indicated by the larger arrow (2).
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3.17  Normal ST Segment and T Waves
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(A) Indicative changes of ischemia, injury, and necrosis seen in leads
facing the injured area.
(B) Reciprocal changes often seen in leads not directly facing the involved area.
3.18  Zones of Myocardial Ischemia, Injury, and Infarction with Associated 
ECG Changes
A B
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3.19  ECG Patterns Associated with Myocardial Ischemia
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3.20  ECG Patterns Associated with Acute Myocardial Injury
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3.21  ECG Changes Associated with Myocardial Infarction
Location of MI Indicative Changes Reciprocal changes
Anterior V1-V4 I, aVL, II, III, aVF
Septal V1, V2 I, aVL
Inferior II, III, aVF I, aVL, V1-V4
Posterior None V1-V4
Lateral I, aVL, V5, V6 II, III, aVF, V1, V2
Right ventricle V3R-V6R
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3.22  Typical Plasma Profiles
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CK
(non-Q)
AST LDH
Typical plasma profiles for the MB isoenzymes of creatine kinase (MB-CK), aspartate amino transferase (AST), and lactate dehydrogenase (LDH) activities
following onset of acute myocardial infarction. (Used with permission, Alexander R, Pratt C. Diagnosis and management of acute myocardial infarction. 
In: Fuster V, Alexander R, O’Rouke R, eds. Hurst’s The Heart. 10th ed. New York, NY: McGraw-Hill; 2001.)
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Posterior septal lateral RCA Circumflex Posterior surface Murmurs indicating Lateral Indicative: Bradycardia RV involvement
branches of LV, VSD (septal) ST elevation I, aVL, V5, 6 Mobitz I (posterior) Aneurysm development
(right and SA node 45% PA catheter to assess Loss of R wave and ↑ ST Papillary muscle
left) AV node 10% R to L shunt in VSD in I, aVL, V5-6 dysfunction
Left atrium Signals/symptoms of Posterior Indicative: Heart blocks frequently
Lateral wall of LV LV aneurysm with Tall, broad R waves resolve
lateral displaced (0.04 second) in V1-3 ↑ ST
PMI leading to V4R (right sided 12 lead, 
signs and symptoms V4 position)
of mitral regurgitation Posterior Reciprocal:
ST depression in V1,2, upright
T wave in V1,2
3.23  Clinical Presentation of Myocardial Ischemia and Infarction
Arterial Muscle Area Possible
Type MI Involvement Supplied Assessment ECG Changes Likely Arrhythmias Complications
Anteroseptal wall LAD Anterior LV wall, ↓ LV Function → Indicative: RBBB, LBBB Cardiogenic shock
Anterior LV septum ↓ CO, ↓ BP ST elevation with or without AV blocks VSD
Apex LV ↑ PAD, ↑ PCWP abnormal Q waves in V1-4 Atrial fibrillation or flutter Myocardial rupture
Bundle of His S3 and S4, with HF Loss of R waves in Ventricular tachycardia (VT) Heart blocks may be 
Bundle branches Rales with pulmonary precordial leads Tachycardia (septal) permanent (LBBB)
edema Reciprocal: High mortality associated
ST depression in II, III, aVF. with this location of MI
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Right ventricular RCA RA, RV, Inferior LV Kussmaul’s sign Indicative: First-degree AV block Hypotension requiring
infarction SA Node JVD 1- to 2-mm ST-segment Second-degree AV large volumes initially to
AV Node Hypotension elevation in V4R block, type I maintain systemic
Posterior ↑ SVR, ↓ PCWP ↑ CVP ST- and T-wave elevation Incomplete RBBB pressure. Once RV 
IV septum S3 with noncompliant RV in II, III, aVF Transient CHB contractility improves 
Clear breath sounds Q waves in II, III, aVF Atrial fibrillation fluids will mobilize, 
initially ST-elevation decreases in VT/VF possibly requiring 
Hepatomegaly; peripheral amplitude over V1–6 diuresis
edema: cool, clammy,
pale skin
Arterial Muscle Area Possible
Type MI Involvement Supplied Assessment ECG Changes Likely Arrhythmias Complications
Inferior or RCA RV, RA Symptomatic bradycardia: Indicative: AV blocks; often progress Hiccups
“diaphragmatic” SA Node 50% ↓ BP LOC changes ↑ ST segments in II, III, aVF to CHB which may be Nausea/vomiting
AV Node 90% diaphoresis Q waves in II, III, aVF transient or permanent; Papillary muscle 
RA, RV ↓ CO ↑ PAD ↑ PCWP Reciprocal: Wenckebach; dysfunction
Inferior LV Murmurs: associated ST depression in I, aVL, bradyarrhythmias MR
Posterior with papillary muscle V1-4 Septal rupture (0.5%-1%)
IV Septum dysfunction mid/ RV involvement 
Posterior holosystolic rales, associated with atrial
LBBB pulmonary edema, infarcts especially with 
Posterior nausea atrial arrhythmias
LV
3.23  Clinical Presentation of Myocardial Ischemia and Infarction (continued )
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3.24  Evidence-Based Practice: Acute Coronary Syndrome ST-Elevation MI 
and Non–ST-Elevation MI
Diagnosis
• Diagnosis of AMI is based on two of three findings:a,b
1. History of ischemic-like symptoms
2. Changes on serial ECGs
3. Elevation and fall in level of serum cardiac biomarkers
• Of AMI patients, 50% do not present with ST-segment elevation. Other indicators:a,b
1. ST-segment depression may indicate non–ST-elevation MI (NSTEMI).
2. New LBBB.
3. ST-segment depression that resolves with relief of chest pain.
4. T-wave inversion in all chest leads may indicate NSTEMI with a critical stenosis in the proximal LAD.
Acute Management
• Optimal time for initiation of therapy is within 1 hour of symptom onset. Rarely feasible due to delay in treatment-seeking behavior.a,b
• Initial ECG should be obtained within 10 minutes of emergency department arrival.a,b
• Oxygen, nitroglycerine, and aspirin should be administered if not contraindicated.a,b
• Reperfusion strategy: STEMI only.a,b
1. Fibrinolytic agent should be initiated within 30 minutes of arrival if no contraindication
2. If primary PCI to be done, culprit vessel should be opened within 90 minutes of arrival
• Reperfusion strategy for NSTEMI.a,b
1. Fibrinolytics not recommended
2. PCI to be done within 24 hours of arrival
• Weight-based heparin or low-molecular-weight heparin.a,b
• IV beta-blocker should be given within 12 hours of arrival.a,b
• Lipid-lowering agent should be initiated.a,b
Data compiled from: aAntman, et al (2004); bCasey (2002).
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3.25  Summary of Causes of Axis Deviations
Axis:30° to 90°
• Normal
Left Axis Deviation: 31° to 90°
• Left ventricular hypertrophy
• Left anterior fascicular block
• Inferior myocardial infarction
• Left bundle branch block
• Congenital defects
• Ventricular tachycardia
• Wolff-Parkinson-White syndrome
Right Axis Deviation: 91° to 180°
• Right ventricular hypertrophy
• Left posterior fascicular block
• Right bundle branch block
• Dextrocardia
• Ventricular tachycardia
• Wolff-Parkinson-White syndrome
Indeterminant Axis: 90° to 180°
• Ventricular tachycardia
• Bifascicular block
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3.26  ECG Clues for Differentiating Aberration from Ventricular Ectopy
Aberrancy Ventricular Ectopy
P waves Precede QRS complexes Dissociated from QRS or occur at rate slower than QRS;
if 1:1 V-A conduction is present, retrograde P waves follow
every QRS
Precordial QRS concordance Positive concordance may occur with WPW Negative concordance favors VT; positive concordance favors
VT if WPW ruled out
Fusion or capture beats Strong evidence in favor of VT
QRS axis Often normal; may be deviated to right or left Indeterminant axis favors VT; often deviated to left or right
RBBB QRS morphology Triphasic rsR
 in V1: triphasic qRs in V6 Monophasic R wave or diphasic qR complex in V1: left “rabbit
ear” taller in V1: monophasic QS or diphasic rS in V6
LBBB QRS morphology Narrow R wave (0.04 second) in V1; straight Wide R wave (0.03 second) in V1 or V2; slurring or notching
downstroke of S wave in V1 (often slurs or on downstroke of S wave in V1; delay of greater than
notches on upstroke); usually no Q wave in V6 0.06 second to nadir of S wave in V1 or V2; any Q wave in V6
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3.27  Pacemaker Codes
First Letter: Second Letter: Third Letter: Fourth Letter: Fifth Letter:
Chamber Paced Chamber Sensed Response to Sensing Rate Modulation Multisite Pacinga
0  None 0  None 0  None 0  None 0  None
A  Atrium A  Atrium I  Inhibited R  Rate modulation A  Atrial
V  Ventricle V  Ventricle T  Triggered V  Ventricular
D  Dual (A&V) D  Dual (A&V) D  Dual (I&T) D  Dual
a Multiside indicates either pacing in both atria or both ventricles or pacing multiple sites with a chamber.
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3.28  Dual-Chamber Pacing Modes
Mode Chamber(s) Paced Chamber(s) Sensed Response to Sensing
DVI Atrium and ventricle Ventricle Inhibited
VDD Ventricle Atrium and ventricle Atrial sensing triggers ventricular pacing
Ventricular sensing inhibits ventricular pacing
DDI Atrium and ventricle Atrium and ventricle Inhibited
DDD Atrium and ventricle Atrium and ventricle Atrial sensing inhibits atrial pacing, triggers ventricular pacing
Ventricular sensing inhibits atrial and ventricular pacing
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4.1  Intra-Aortic Balloon Pump Frequency of 1:2
Unassisted systole
Unassisted aortic
end-diastolic
pressure
Assisted aortic
end-diastolic
pressure
Assisted
systole
Diastolic
augmentation
140
120
100
80
mm
Hg
(Datascope Corporation: Mechanics of intra-aortic balloon counterpulsation. Montvale, NJ: Datascope, 1989.)
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4.2  Intra-Aortic Balloon Pump Frequency of 1:1
Assisted aortic
end-diastolic
pressure
Assisted
systole
Assisted
systole
Diastolic
augmentation140
120
100
80
mm
Hg
(Datascope Corporation: Mechanics of intra-aortic balloon counterpulsation. Montvale, NJ: Datascope, 1989.)
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4.3  Inaccurate Intra-Aortic Balloon Pump Timing
Assisted aortic
end-diastolic
pressure
Assisted aortic
end-diastolic
pressure
Assisted
systole
Assisted
systole
Unassisted
systole
Unassisted
systole
Diastolic
augmentation Diastolic
augmentation
A B
Dicrotic
notch
(A) Early inflation. (B) Late inflation.
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(C) Early deflation. (D) Late deflation. (Datascope Corporation: Mechanics of intra-aortic balloon counterpulsation. Montvale, NJ: Datascope, 1989.)
Unassisted
aortic
end-diastolic
pressure
Assisted aortic
end-diastolic
pressure
Assisted aortic
end-diastolic
pressure
Assisted
systole Unassisted
systole
Diastolic
augmentation Diastolic
augmentation
Widened
appearance
Prolonged rate
of rise of
assisted systole
DC
4.3  Inaccurate Intra-Aortic Balloon Pump Timing (continued )
4.4  Advanced Cardiovascular Life Support (ACLS) Pulseless Arrest Algorithm
89
1
2
3
Pulseless arrest
• BLS algorithm: Call for help, give CPR
• Give oxygen when available
• Attach monitor/defibrillator when available
Check rhythm
Shockable rhythm?
Asystole/PEAVF/VT
Shockable Not shockable
9
(continued )
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4
5
6
7
12
13
8
Check rhythm
Shockable rhythm?
Check rhythm
Shockable rhythm?
Check rhythm
Shockable rhythm?
Give 1 shock
• Manual biphasic: Device specific
 (typically 120-200 J)
 Note: If unknown, use 200 J
• AED: Device specific
• Monophasic: 360 J
Resume CPR immediately
Continue CPR while defibrillator is charging
Give 1 shock
• Manual biphasic: Device specific
 (same as first shock or higher dose)
 Note: If unknown, use 200 J
• AED: Device specific
• Monophasic: 360 J
Resume CPR immediately after the shock
when IV/IO available, give vasopressor during CPR
(before or after the shock)
• Epinephrine 1 mg IV/IO
Repeat every 3-5 minutes
  or
• May give 1 dose of vasopressin 40 U IV/IO to
 replace first or second dose of epinephrine
Resume CPR immediately for 5 cycles
when IV/IO available, give vasopressor
• Epinephrine 1 mg IV/IO
Repeat every 3-5 minutes
  or
• May give 1 dose of vasopressin 40 U IV/IO to
 replace first or second dose of epinephrine
Consider atropine 1 mg IV/IO
 for asystole or slow PEA rate
 repeat every 3-5 minutes (up to 3 doses)
• If asystole, go to box 10
• If electrical activity, check
 pulse; if no pulse, go to
 box 10
• If pulse present, begin
 postresuscitation care
Go to
box 4
Not
shockable Shockable
10
11
Give 5 cycles of CPR
Give 5 cycles of CPR
Give 5 cycles of CPR
Shockable
Shockable
No
No
4.4  Advanced Cardiovascular Life Support (ACLS) Pulseless Arrest Algorithm (continued )
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8
Continue CPR while defibrillator is charging
Give 1 shock
• Manual biphasic: Device specific
(same as first shock or higher dose)
 Note: If unknown, use 200 J
• AED: Device specific
• Monophasic: 360 J
Resume CPR immediately after the shock
Consider antiarrhythmics; give during CPR
 (before or after the shock)
amiodarone (300 mg IV/IO once, then
 consider additional 150 mg IV/IO once) or
lidocaine (1-1.5 mg/kg first dose, then 0.5-
 0.75 mg/kg IV/IO, maximum 3 doses or 3 mg/kg)
Consider magnesium, loading dose
 1 to 2 g IV/IO for torsades de pointes
After 5 cycles of CPR, go to box 5 above
During CPR
• Push hard and fast (100/min)
• Ensure full chest recoil
• Minimize interruptions in chest
 compressions
• One cycle of CPR: 30 compressions
 then 2 breaths; 5 cycles ≈2 minutes
• Avoid hyperventilation
• Secure airway and confirm placement
* After an advanced airway is placed,
 rescuers no longer deliver “cycles”
 of CPR; give continuous chest com-
 pressions without pauses for breaths;
 give 8-10 breaths/min; check
 rhythm every 2 minutes
• Rotate compressors every
 2 minutes with rhythm checks
• Search for and treat possible
 contributing factors:
- Hypovolemia
- Hypoxia
- Hydrogen ion (acidosis)
- Hypo-/hyperkalemia
- Hypoglycemia
- Hypothermia
- Toxins
- Tamponade, cardiac
- Tension pneumothorax
- Thrombosis (coronary or
 pulmonary)
- Trauma
Shockable
(Used with permission from 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and
Emergency Cardiovascular Care. Circultion. Dec 13, 2005;112[24 suppl]:IV59. http://circ.ahajournals.org/con-
tent/vol112/24_suppl/. Accessed July 15, 2009.) Abbreviations: AED, automated external defibrillator; BLS, basic life
support; CPR, cardiopulmonary resuscitation; IO, intraosseous; IV, intravenous; PEA, pulseless electrical activity;
U, units; VF, ventricular fibrillation; VT, ventricular tachycardia.
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4.5  Advanced Cardiovascular Life Support (ACLS) Bradycardia Algorithm
• Maintain patent airway; assist breathing as needed
• Give oxygen
• Monitor ECG (identify rhythm), blood pressure, oximetry 
• Establish IV access
3
2
1
Bradycardia
Heart rate <60 bpm and
inadequate for clinical condition
Signs or symptoms of poor perfusion caused by the bradycardia? 
(eg, acute altered mental status, ongoing chest pain, hypotension, or other signs of shock)
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Reminders
•  If pulseless arrest develops, go to pulseless arrest algorithm
•  Search for and treat possible contributing factors:
– Hypovolemia
– Hypoxia
– Hydrogen ion (acidosis)
– Hypo-/hyperkalemia
– Hypoglycemia
– Hypothermia
– Toxins
– Tamponade, cardiac
– Tension pneumothorax
– Thrombosis (coronary or pulmonary)
– Trauma (hypovolemia, increased ICP)
•  Prepare for transvenous pacing 
•  Treat contributing causes
•  Consider expert consultation
5
•  Prepare for transcutaneous pacing;
   Use without delay for high-degree block
   (type II second-degree block or
   third-degree AV block) 
•  Consider atropine 0.5 mg IV while
   awaiting pacer; may repeat to a
   total dose of 3 mg; if ineffective,
   begin pacing
• Consider epinephrine (2-10 mcg/min)
   or dopamine (2-10 mcg/kg/min)
   infusion while awaiting pacer or if 
   pacing ineffective
Poor
Perfusion 
Adequate
Perfusion
Observe/Monitor
4A 4
(Used with permission from 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovas-
cular Care. Circulation. Dec 13, 2005;112[24 suppl]:IV68. http://circ.ahajournals.org/content/vol112/24_suppl/. Accessed July 15, 2009.) Ab-
breviations: IV, intravenous; mcg, micrograms.
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4.6  Advanced Cardiovascular Life Support (ACLS) Tachycardia Algorithm
Tachycardia
with pulses
• Assess and support ABCs as needed
• Give oxygen
• Monitor ECG (identify rhythm), blood pressure, oximetry
• Identify and treat reversible causes
Symptoms persist
Stable Unstable
• Establish IV access
• Obtain 12-lead ECG
(when available) or rhythm strip
Is QRS narrow
(<0.12 second)?
Is patient stable?
Unstable signs include altered
mental status, ongoing chest pain,
hypotension, or other signs of shock
Note: rate-related symptoms
uncommon if heart rate
<150 beats/minutes
Perform immediate
synchronized cardioversion
• Establish IV access and give
 sedation if patient
 is conscious; do not delay
 cardioversion
• Consider expert consultation
• If pulseless arrest develops,
 see pulseless arrest algorithm
Narrow
Narrow QRS*:
Is rhythm regular?
Regular Irregular
Wide (≥0.12 seconds)
Wide QRS*:
Is rhythm regular?
Expert consultation
advised
1
4
2
5
6
7 11
3
12
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Regular
Regular
Irregular
Irregular
• Attempt vagal maneuvers
• Give adenosine 6-mg rapid
IV push. If no conversion,
give 12-mg rapid IV push;
may repeat 12 mg dose once
Does rhythm
convert?
Note: Consider
expert consultation
Converts Does not convert
If rhythm converts.
probable reentry SVT
(reentry supraventricular
tachycardia):
• Observe for recurrence
• Treat recurrence with
 adenosine or longer-
 acting AV nodal-blocking
 agents (eg, diltiazem.
 β-blockers)
If rhythm does not convert,
possible atrial flutter,
extopic atrial tachycardia,
or junctional tachycardia:
• Control rate (eg, diltiazem,
β-blockers; use β-blockers
 with caution in pulmonary
 disease or HF)
• Treat underlying cause
• Consider expert consultation
Irregular narrow-complex
tachycardia
Probable atrial fibrillation or
possible atrial flutter or MAT
(multifocal atrial tachycardia)
• Consider expert consultation
• Control rate (eg, diltiazem,
β-blockers; use β-blockers with
caution in pulmonary disease
or HF)
Note: If patient becomes
unstable, go to Box 4.
During evaluation Treat contributing factors:
• Secure, verify airway
 and vascular access
 when possible
• Consider expert
 consultation
• Prepare for
 cardioversion
- Hypovolemia
- Hypoxia
- Hydrogen ion (acidosis)
- Hypo-/hyperkalemia
- Hypoglycemia
- Hypothermia
- Toxins
- Tamponade, cardiac
- Tension pneumothorax
- Thrombosis (coronary or
 pulmonary
- Trauma (hypovolemia)
advised
If ventricular
tachycardia or
uncertain rhythm
• Amiodarone
 150 mg IV over
 10 minutes
 repeat as needed
 to maximum dose of
 2.2 g/24 hours
• Prepare for elective
 synchronized
 cardioversion
If SVT with aberrancy
• Give adenosine
 (go to Box 7)
If atrial fibrillation with
aberrancy
• See irregular narrow-
 complex tachycardia
 (Box 11)
If pre-excited atrial
fibrillation (AF + WPW)
• Expert consultation
 advised
• Avoid AV nodal
 blocking agents (eg,
adenosine, digoxin,
 diltiazem, verapamil)
• Consider antiarrhyth-
 mics (eg, amiodarone
 150 mg IV over 10 minutes)
If recurrent polymor-
phic VT, seek expert
consultation
If torsade de pointes,
give magnesium
(load with 1-2 g over
5-60 minutes, then infusion)
7 11
8
9 10
13 14
(Used with permission from 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circula-
tion. Dec 13, 2005;112[24 suppl]:IV70. http://circ.ahajournals.org/content/vol112/24_suppl/. Accessed July 15 2009.) Abbreviations: AF, atrial 
fibrillation; HF, heart failure; SVT, supraventricular tachycardia; WPW, Wolff-Parkinson-White.
96
4.7  Problems Encountered with Arterial Catheters
Problem Cause Prevention Treatment
Hematoma after 
withdrawal of needle
Decreased or absent 
pulse distal to 
puncture site
Bleedback into tubing 
or transducer
Bleeding or oozing at 
puncture site
Spasm of artery
Thrombosis of artery
Insufficient pressure on IV bag
Loose connections
Maintain firm pressure on site during 
withdrawal of catheter and for 
5-15 minutes (as necessary) after
withdrawal.
Apply elastic tape (Elastoplast) firmly 
over puncture site.
For femoral arterial puncture sites, 
leave a sandbag on site for 1-2 hours
to prevent oozing.
If patient is receiving unfractionated, 
discontinue 2 hours before catheter
removal.
Introduce arterial needle cleanly, 
nontraumatically.
Use 1 U of unfractionated/1 mL 
IV fluid.
Maintain 300 mm Hg pressure on 
IV bag.
Use Luer-Lock stopcocks; tighten 
periodically.
Continue to hold pressure to puncture 
site until oozing stops.
Apply sandbag to femoral puncture site 
for 1-2 hours after removal of
catheter.
Call physician to inject lidocaine locally 
at insertion site and 10 mg into arterial
catheter.
Arteriotomy and Fogarty catheterization 
may be needed both distally and
proximally from the puncture site result
in return of pulse in 90% of cases if
brachial or femoral artery is used.
Replace transducer. “Fast flush” 
through system.
Tighten all connections.
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Hemorrhage
Emboli
Local infection
Sepsis
Adapted from: Daily E, Schroeder J. Techniques in Bedside Hemodynamic Monitoring. 5th ed. St Louis, MO: CV Mosby; 1994: 165-166.
4.7  Problems Encountered with Arterial Catheters (continued )
Problem Cause Prevention Treatment
Loose connections
Clot from catheter tip into 
bloodstream
Forward movement of 
contaminated catheter
Break in sterile technique
Prolonged catheter use
Break in sterile technique
Prolonged catheter use
Bacterial growth in IV fluid
Keep all connecting sites visible. Observe
connecting sites frequently. Use built-in
alarm system. Use Luer-Lock stopcocks.
Always aspirate and discard before flushing.
Use continuous flush device. Gently flush
2-4 mL.
Carefully secure catheter at insertion site.
Always use aseptic technique.
Leave dressing in place until catheter is
removed, changed, or dressing
becomes damp, loosened, or soiled.
Use percutaneous insertion. Always use
aseptic technique.
Change IV fluid bag, stopcocks,
transducer, and tubing every 72 hours.
Do not use IV fluid containing glucose.
Use a closed-system flush system
rather than an open system Carefully
flush remaining blood from stopcocks
after blood sampling.
Tighten all connections.
Remove catheter.
Remove catheter.
Prescribe antibiotic.
Remove catheter.
Prescribe antibiotic.
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4.8  Inaccurate Arterial Pressure Measurements
Problem Cause Prevention Treatment
Damped pressure tracing Catheter tip against vessel wall Usually cannot be avoided. Call physician to pull back, rotate,  
or reposition catheter while
observing pressure waveform.
Partial occlusion of catheter tip by clot Use continuous infusion under Aspirate clot with syringe and flush 
pressure. Briefly “fast flush” with saline (2-4 mL). Consider 
after blood withdrawal (2-4 mL). line removal.
Clot in stopcock or transducer Carefully flush catheter after blood Flush stopcock and transducer; if no 
withdrawal and reestablish IV improvement, change stopcock and 
drip. Use continuous flush device. transducer.
Air bubbles in transducer or connector Carefully flush transducer and tubing Check system; flush rapidly; disconnect
tubing when setting up system and attaching transducer and flush out air bubbles.
to catheter.
Compliant tubing Use stiff, short tubing. Shorten tubing or replace softer
tubing with stiffer tubing.
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Abnormally high or low Change in transducer air-reference Maintain air-reference port of Recheck patient and transducer 
readings level transducer at midchest and/or  positions.
catheter tip level for serial 
pressure measurements.
No pressure available Transducer not open to catheter Follow routine, systematic steps for Check system—stopcocks, monitor, 
Settings on monitor amplifiers setting up system and turning and amplifier setup.
incorrect—still on zero, cal, or off stopcocks.
Incorrect scale selection Select scale appropriate to expected Select appropriate scale.
range of physiologic signal.
Adapted from: Daily E, Schroeder J. Techniques in Bedside Hemodynamic Monitoring. 5th ed. St Louis, MO: CV Mosby; 1994:161
4.8  Inaccurate Arterial Pressure Measurements (continued )
Problem Cause Prevention Treatment
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4.9  Pulmonary Artery Port Functions
Type of Port Functions
Distal tip port Measures pressure at the tip of the catheter in the PA. With proper inflation of the balloon, measures the 
pulmonary capillary wedge pressure (PCWP).
Used to sample SvO2 levels and for other blood sampling needs.
Proximal lumen port Measures pressure 30 cm from the distal tip, usually in the right atrium (RA). Central venous pressure (CVP)
and RA pressure (RAP) are synonymous terms.
Injection site for cardiac output (CO) determinations.
Used to draw blood samples for laboratory tests requiring venous blood. If coagulation studies are drawn, 
completely remove unfractionated heparin from line prior to obtaining sample.
Used for IV fluids and drug administration, if necessary.
Balloon inflation port Inflated periodically with 1.5 mL of air to obtain PCWP tracing.
Ventricular port (on selected Measures right ventricle (RV) pressure.
models of PA catheters) Used for insertion of a temporary pacemaker electrode in the RV.
Ventricular infusion port (on selected An additional lumen for IV fluid or drug administration. Located close to the proximal lumen exit area.
models of PA catheters) May be used for CO determinations or CVP measurements, if necessary.
Cardiac output port (thermistor lumen) Measures blood temperature near the distal tip when connected to the cardiac output computer.
May be used to monitor body (core) temperature continuously.
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4.10  Leveling of the PA Catheter
Stopcock open
to atmosphere
Midaxillary Line
(where distance “A” = distance “B”)
Typical leveling of PA catheter with stopcock attached to the transducer for mounting on a pole. The stopcock close to the
transducer is opened to atmospheric pressure (air) horizontal to the fourth ICS at the midaxillary line.
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60°
30°
0°
A
(A) The level of the phlebostatic axis as the patient moves flat to a higher level of backrest. The level of the axis for referencing and zeroing the air-fluid inter-
face rotates on the axis and remains horizontal as the patient moves from flat to increasingly higher backrest positions. For accurate hemodynamic pressure
readings at different backrest elevations, the air-fluid interface must be at the level of the phlebostatic axis. (From Bridges EJ, Woods SL. Pulmonary artery pres-
sure measurement: state of the art. Heart Lung. 1993;22[2]:101.) (B) For the right lateral position, the reference point is at the intersection of the fourth ICS and
the midsternum. (C) For the left lateral position, the reference point is the intersection of the fourth ICS and the left parasternal border. (From Keckeisen M,
Chulay M, Gawlinski A, eds. Pulmonary artery pressure monitoring. In: Hemodynamic Monitoring Series. Aliso Viejo, CA: AACN; 1998:12.)
C
B
4.11  Referencing and Zeroing the Hemodynamic Monitoring System
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4.12  Assessing Damping Concepts from Square Wave Test
Square Wave Test Clinical Effect Corrective Action
Optimally damped Produces accurate waveform None required.
and pressure.
Optimally damped system. When the fast flush
of the continuous flush system is activated
and quickly released, a sharp upstroke termi-
nates in a flat line at the maximal indicator on
the monitor and hard copy. This is followed
by an immediate and rapid downstroke ex-
tending below the baseline with just 1 or 2 os-
cillations within 0.12 second (minimal ringing)
Observed
waveform
and a quick return to baseline. The patient’s pressure waveform is also clearly
defined with all components of the waveform, such as the dicrotic notch on
an arterial waveform, clearly visible. Intervention: There is no adjustment in the
monitoring system required. (Reprinted from Darovic GO, Vanriper S, Vanriper
J. Fluid-filled monitoring systems. In: Darovic GO, ed. Hemodynamic Monitoring:
Invasive and Noninvasive Clinical Application. 3rd ed. Philadelphia, PA: WB
Saunders Co; 1995:161-162. Used with permission from Elsevier.)
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Observed
waveform
Overdamped Produces a falsely low Check the system for air, blood,
systolic and high loose connections or kinks
diastolic value. in the tubing or catheter.
Verify extension tubing has not
been added.
4.12  Assessing Damping Concepts from Square Wave Test (continued )
Square Wave Test Clinical Effect Corrective Action
well as poorly defined components of the pressure tracing such as a dimin-
ished or absent dicrotic notch on arterial waveforms. Interventions: To cor-
rect the problem, (1) check for the presence of blood clots, blood left in the
catheter following blood sampling, or air bubbles at any point from the
catheter tip to the transducer and eliminate them as necessary; (2) use low
compliance (rigid), short (3-4 ft) monitoring tubing; (3) ensure there are no
loose connections; and (4) check for kinks in the line. (Reprinted from
Darovic GO, Vanriper S, Vanriper J. Fluid-filled monitoring systems. In:
Darovic GO, ed. Hemodynamic Monitoring: Invasive and Noninvasive Clini-
cal Application. 3rd ed. Philadelphia, PA: WB Saunders Co; 1995:161-162.
Used with permission.)
Overdamped system. The upstroke of the
square wave appears somewhat slurred, the
waveform does not extend below the base-
line after the fast flush, and there is no ring-
ing after the flush. The patient’s waveform
displays a falsely decreased systolic pres-
sure and a falsely high diastolic pressure as
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Observed
waveform
Underdamped Produces a falsely high Remove unnecessary tubing 
systolic and low and stopcocks.
diastolic value. Add a damping device.
4.12  Assessing Damping Concepts From Square Wave Test (continued )
Square Wave Test Clinical Effect Corrective Action
system. Use large bore, shorter tubing, or a damping device. (Reprinted from
Darovic GO, Vanriper S, Vanriper J. Fluid-filled monitoring systems. In:
Darovic GO, ed. Hemodynamic Monitoring: Invasive and Noninvasive Clini-
cal Application. 3rd ed. Philadelphia, PA: WB Saunders Co; 1995:161-162.
Used with permission from Elsevier.)
Underdamped system. The waveform is
characterized by numerous amplified oscilla-
tions above and below the baseline following
the fast flush. The monitored pressure wave
displays falsely high systolic pressure
(overshoot), possibly falsely low diastolic
pressures, and “ringing” artifacts on the
waveform. Intervention: To correct the
problem, remove all air bubbles in the fluid
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4.13  Pressure Waveforms Observed During Pulmonary Artery Catheter Insertion
Location Pressure Waveform Normal Pressures
Right atrium 2-8 mm Hg
Right ventricle Systolic, 20-30 mm Hg
Diastolic, 0-5 mm Hg
60
40
20
0
60
40
20
0
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4.13  Pressure Waveforms Observed During Pulmonary Artery Catheter Insertion (continued )
Location Pressure Waveform Normal Pressures
Pulmonary artery Systolic, 20-30 mm Hg
Diastolic, 10-15 mm Hg
Pulmonary artery wedge 8-12 mm Hg
With permission from: Boggs R, Wooldridge-King M. AACN Procedure Manual. 3rd ed. Philadelphia, PA: WB Saunders; 1993:308, 324, 326, 334.
60
40
20
0
60
40
20
0
108
1, PA systole; 2, dichrotic notch; 3, PA end diastole; 4, anacrotic notch of PA valve opening. (From: Boggs R, Wooldridge-
King M. AACN Procedure Manual for Critical Care, 3rd ed. Philadelphia, PA: WB Saunders; 1993:316.)
4.14  Pulmonary Artery Waveform and Components
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(From: Ahrens TS. Hemodynamic Waveform Recognition. Philadelphia, PA: WB Saunders; 1993:92.)
4.15  Effect of a Mechanical Ventilator Breath on PA Waveform
110
(From: Ahrens TS, Taylor L: Hemodynamic Waveform Analysis. Philadelphia: WB Saunders; 1992:170.)
4.16  Reading End Expiration Before a Spontaneous Breath
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4.17  Evidence-Based Practice: Pulmonary Artery Pressure Measurement
• Verify the accuracy of the transducer-patient interface by performing a square waveform test at the beginning of each shift.a,b
• Position the patient supine prior to PAP/RAP (CVP)/PCWP measurements. Head of bed elevation can be at any angle from 0° (flat) to 60°.a,b
• Level the transducer air-fluid interface to the phlebostatic axis (4th ICS/1⁄2 AP diameter of the chest) with the patient in a supine position prior to
PAP/RAP/PCWP measurements.a,b
• Obtain PAP/RAP/PCWP measurements from a graphic (analog) tracing at end-expiration.a,b
• Use a simultaneous ECG tracing to assist with proper PAP/RAP/PCWP waveform identification.a,b
• PA catheters can be safely withdrawn and removed by competent registered nurses.a,b
Data from: aAmerican Association of Critical-Care Nurses (2004); bKeckeisen (1998).
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Phlebitis or local infection 
at insertion site
Ventricular irritability
Mechanical irritation or contamination
Looping of excess catheter in RA
Migration of catheter from PA to RV
Irritation of the endocardium during 
catheter passage
Prepare skin properly before insertion. 
Use sterile technique during insertion
and dressing change. Insert smoothly
and rapidly. Use Teflon-coated
introducer. Change IV fluid bag,
transducer, stopcocks, and connecting
tubing every 72 hours. Remove
catheter or change insertion site.
Carefully secure catheter at insertion 
site; check chest film.
Position catheter tip in main right or
left PA.
Keep balloon inflated during 
advancement; advance gently.
Remove catheter.
Apply warm compresses.
Give pain medication as necessary.
Call physician to reposition catheter; 
remove loop.
Inflate balloon to encourage catheter 
flotation out to PA.
4.18  Problems Encountered with Pulmonary Artery Catheters
Problem Cause Prevention Treatmen
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4.18  Problems Encountered with Pulmonary Artery Catheters (continued )
Problem Cause Prevention Treatment
Apparent wedging of 
catheter with balloon 
deflated
Aspirate blood from catheter; if 
catheter is wedged, sample will be
arterialized and obtained with
difficulty.
If wedged, call physician to slowly pull 
back catheter until PA waveform
appears. If not wedged, gently
aspirate and flush catheter with
saline; catheter tip can partially clot,
causing damping that resembles
damped PAW waveform.
Forward migration of catheter tip
caused by blood flow, excessive loop
in RV, or inadequate suturing of
catheter at insertion site
Check catheter tip by radiograph or 
fluoroscopy; position in main right
or left PA. Carefully secure catheter
at insertion site.
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4.18  Problems Encountered with Pulmonary Artery Catheters (continued )
Problem Cause Prevention Treatment
Pulmonary hemorrhage 
or infarction, or both
Distal migration of catheter tip
Continuous or prolonged wedging of 
catheter
Overinflation of balloon while catheter 
is wedged
Failure of balloon to deflate
Check chest film immediately after 
insertion.
Leave balloon deflated.
Carefully secure catheter at insertion 
site.
Call physician to pull catheter back to 
PA if it spontaneously wedges.
Do not flush catheter when in wedge
position.
Inflate balloon slowly with only enough
air to obtain a PAW waveform.
Do not inflate 7-Fr catheter with more 
than 1.25-1.5 mL air.
Deflate balloon (passively).
Place patient on side (catheter tip 
down).
Stop anticoagulation.
Consider “wedge” angiogram.
115
4.18  Problems Encountered with Pulmonary Artery Catheters (continued )
Problem Cause Prevention Treatment
“Overwedging” or damped 
PAW
Overinflation of balloon
Eccentric inflation of balloon
Do not inflate if resistance is met.
Watch waveform during inflation; 
inject only enough air to obtain PAW
pressure.
Do not inflate 7-Fr catheter with more 
than 1.25-1.5 mL air.
Check inflated balloon shape before 
insertion.
Deflate balloon; reinflate slowly with 
only enough air to obtain PAW
pressure.
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4.18  Problems Encountered with Pulmonary Artery Catheters (continued )
Problem Cause Prevention Treatment
PA balloon rupture
Infection
Overinflation of balloon
Frequent inflations of balloon
Syringe deflation damaging wall of
balloon
Nonsterile insertion techniques
Contamination via skin
Contamination through stopcock
ports or catheter hub
Inflate slowly with only enough air to 
obtain a PAW pressure.
Monitor PAD pressure as reflection of 
PAW and LVEDP.
Allow passive deflation of balloon.
Remove syringe after inflation.
Use sterile techniques.
Use sterile catheter sleeve.
Prepare skin with effective antiseptic 
(chlorhexidine).
Reassess need for catheter after 
3 days.
Avoid internal jugular approach.
Use a closed-system flush system 
rather than an open system.
Use sterile dead-end caps on all 
stopcock ports.
Change tubing, continuous flush 
device transducer, and flush solution
every 72 hours.
Do not use IV flush solution that 
contains glucose.
Remove syringe to prevent further air 
injection.
Monitor PAD pressure.
Remove catheter.
Use antibiotics.
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4.18  Problems Encountered with Pulmonary Artery Catheters (continued )
Problem Cause Prevention Treatment
Heart block during insertion 
of catheter
Abbreviations: PA, pulmonary artery; PAW, pulmonary artery wedge; RV, right ventricle; 
Adapted from: Daily E, Schroeder J. Techniques in Bedside Hemodynamic Monitoring. 5th ed. St Louis, MO: CV Mosby; 1994:134-135
Fluid contamination from transducer
through cracked membrane 
Prolonged catheter placement
Mechanical irritation of bundle of His in
patients with preexisting left bundle
branch block
Check transducer for cracks.
Change transducers every 72 hours.
Do not use IV flush solution that 
contains glucose.
Change catheter and/or insertion site 
with any local signs of infection and
for infections without an obvious
source (should obtain cultures).
Remove catheter as soon as clinically 
feasible.
Catheter should be advanced 
expeditiously during insertion with 
balloon inflated.
Insert transvenous pacing catheter 
before PA catheter insertion.
Use temporary pacemaker or flotation
catheter with pacing wire.
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4.19  Inaccurate Pulmonary Artery Pressure Measurements
Problem Cause Prevention Treatment
Damped waveforms and 
inaccurate pressures
Partial clotting at catheter tip
Tip moving against wall
Kinking of catheter
Maintain adequate flush bag pressures.
Flush with large volume after blood
sampling.
Obtain more stable catheter position.
Restrict catheter movement at 
insertion site.
Aspirate, then flush catheter with fast 
flush (not in PAW position).
Call physician to reposition catheter.
Reposition to straighten catheter. 
Replace catheter.
119
4.19  Inaccurate Pulmonary Artery Pressure Measurements (continued )
Problem Cause Prevention Treatment
Abnormally low or negative 
pressures
Abnormally high pressure 
reading
Inappropriate pressure 
waveform
Incorrect air-reference level (above 
midchest level)
Incorrect zeroing and calibration of 
monitor
Loose connection
Pressure trapped by improper 
sequence of stopcock operation
Incorrect air-reference level (below 
midchest level)
Migration of catheter tip (eg, in RV 
or PAW instead of in PA)
Maintain transducer air-reference port 
at midchest level; rezero after patient
position changes.
Zero and calibrate monitor properly.
Use Luer-Lock stopcocks.
Use Luer-Lock stopcocks.
Turn stopcocks in proper sequence 
when two pressures are measured
on one transducer.
Maintain transducer air-reference port
at midchest level; recheck and rezero
after patient position changes.
Establish optimal position carefully 
when introducing catheter initially.
Secure catheter at insertion site and
tape catheter to patient’s skin.
Remeasure level of transducer 
air-reference and reposition at
midchest level; rezero.
Recheck zero and calibration of 
monitor.
Check all connections.
Thoroughly flush transducers with IV 
solution; rezero and turn stopcocks
in proper sequence.
Check air-reference level; reset at 
midchest and rezero.
Review waveform; if RV, call 
physician to reposition catheter.
Check position under x-ray and/or
fluoroscopy after reposition.
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4.19  Inaccurate Pulmonary Artery Pressure Measurements (continued )
Problem Cause Prevention Treatment
No pressure available
Noise or fling in pressure 
waveform
Abbreviations: PA, pulmonary artery; PAW, pulmonary artery wedge; RV, right ventricle.
Adapted from: Daily E, Schroeder J. Techniques in Bedside Hemodynamic Monitoring. 5th ed. St Louis, MO: CV Mosby; 1994:137.
Transducer not open to catheter
Amplifiers still on cal, zero, or off
Excessive catheter movement,
particularly in PA
Excessive tubing length
Excessive stopcocks
Follow routine, systematic steps for 
pressure measurement.
Avoid excessive catheter length in
ventricle.
Use shortest tubing possible (3-4 ft).
Minimize number of stopcocks.
Check system, stopcocks.
Try different catheter tip position.
Eliminate excess tubing.
Eliminate excess stopcocks.
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Injectate volume greater than designated amount
Catheter tip in RV or RA
Incorrect variables entered into monitor
Left-to-right shunt (VSD)
Catheter kinked or thermistor partially obstructed 
with clot
Faulty catheter (communication between proximal 
and distal lumens)
Inject exact volume to correspond to computation constant used.
Discontinue rapid infusion through proximal or distal port.
Verify PA waveform from distal lumen. Reposition catheter.
Recheck and correct variables (height, weight).
Check RA and PA oxygen saturations.
Use alternative CO measurement technique.
Check for kinks at insertion site; straighten catheter; aspirate and
flush catheter. Replace catheter.
4.20  Troubleshooting Problems with Thermodilution Cardiac Output Measurements
Problem Cause Action
Cardiac output values
lower than expected
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4.20  Troubleshooting Problems with Thermodilution Cardiac Output Measurements (continued )
Problem Cause Action
Cardiac output values 
higher than expected
Injectate volume less than designated amount
Catheter too distal (PAW)
RA port lies within sheath
Thermistor against wall of PA 
Fibrin covering thermistor 
Incorrect  variables
Right-to-left shunt (VSD)
Severe tricuspid regurgitation
Incorrect injectate temperature
Inject exact volume to correspond to computation constant.
Carefully remove all air bubbles from syringe.
Verify PA waveform from distal lumen.
Pull catheter back.
Advance catheter.
Reposition patient.
Rotate catheter to turn thermistor away from wall.
Reposition catheter.
Check a-vDo2; change catheter.
Recheck and correct variables (height, weight).
Use alternative CO measurement technique.
Use closed injectate system with in-line temperature probe.
Handle syringe minimally.
Do not turn stopcock to reestablish IV infusion through proximal
port between injections; reduce or discontinue IV flow
through VIP port.
Try to determine cause of interference.
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4.20  Troubleshooting Problems with Thermodilution Cardiac Output Measurements (continued )
Problem Cause Action
Irregular upslope of 
CO curve
Magnetic interference producing numerous spikes in
CO curve
Long lag time between injection and upstroke of 
curve
Uneven injection technique
RA port partially occluded with clot
Catheter partially kinked
Press start button after injection completed to delay computer 
sampling time.
Inject smoothly and quickly (10 mL in 4 seconds).
Always check catheter patency by withdrawing, then flushing 
proximal port before CO determinations.
Check for kinks, particularly at insertion site; straighten catheter; 
reposition patient.
1244.20  Troubleshooting Problems with Thermodilution Cardiac Output Measurements (continued )
Problem Cause Action
Irregular downslope 
of CO curve
Abbreviations: AV, atrioventricular; CO, cardiac output; CPR, cardiopulmonary resuscitation; ECG, electrocardiogram; IV, intravenous; NSR, normal sinus
rhythm; MAT, multifocal atrial tachycardia; PAC, premature atrial contraction; PJC, premature junctional complex; PVC, premature ventricular complexes; VT,
ventricular tachycardia.
Adaption from: Daily E, Schroeder J. Techniques in Bedside Hemodynamic Monitoring. 5th ed. St Louis, MO; CV Mosby; eds, 1994: 183–184 Cardiac output
waveforms from: Gardner P. Cardiac output: theory, technique and troubleshooting. In: Underhill SL, Woods S, Froelicher E, et al. Cardiac Nursing. 2nd ed. 
Philadelphia, PA: JB Lippincott; 1989:465.
Cardiac arrhythmias (PVC, AF, etc)
Marked movement of catheter tip
Marked variation in PA baseline temperature
Curve prematurely terminated
Right-to-left shunt
Note ECG during CO determinations.
Try to inject during a stable period.
Increase the number of CO determinations.
Obtain x-ray film to determine position of tip.
Advance catheter tip away from pulmonic value.
Use iced temperature injectate to increase signal/noise ratio.
Increase the number of CO determinations.
Inject at various times during respiratory cycle.
Press start button after injection completed to delay computer 
sampling time.
Use alternative CO measurement technique.
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4.21  Common Inotropic Therapies in
Treating Abnormal
Hemodynamics
Onset of
Drug Dosage Action Route
Dobutamine 1-20 mcg/kg/min 1-2 minutes IV
(Dobutrex)
Dopamine (Intropin) 2-10 mcg/kg/min 1-2 minutes IV
Milrinone (Primacor) Loading 0.75 mg/kg, 5 minutes IV
then 5-10 mcg/kg/min
Digoxin (Lanoxin) 0.5 mg at first; then
(normally not used 0.25 every 6 hours
in acute LV failure) until desired effect, 1-2 hours IV
then 0.125-0.25 mg/day
4.22  Common Preload Reducers for
Abnormal Hemodynamics
Onset of
Drug Dosage Action Route
Diuretic Agents
Furosemide (Lasix) 20 mg or higher 5 minutes IV/PO
Bumetanide (Bumex) 0.5-10 mg/day 5 minutes IV/PO
Ethacrynic Acid (Edecrin) 50-100 mg/day 5 minutes IV/PO
Chlorothiazide (Diuril) 500-2000 mg/day 1-2 hours IV/PO
Metolazone (Zaroxolyn) 2.5-20 mg/day 1 hour PO
Mannitol (Osmitrol) 12.5-200 g/day 5 minutes IV
Vasodilating Agents
Dopamine (Intropin) 1-2 mcg/kg/min 5 minutes IV
Nitroglycerine 5-400 mcg 1-2 minutes IV
(Tridil, Nitrostat IV)
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4.23  Common Afterload Reducing Agents
Drug Dose Onset of Action Route
Smooth Muscle Relaxants and Alpha Inhibitors
Nitroprusside (Nipride) 0.5-10 mcg/kg/min 1-2 minutes IV
Nitroglycerine (Tridil, Nitrostat IV) 5-400 mcg 1-2 minutes IV
Diazoxide (Hyperstat IV) 50-150 mg 1-2 minutes IV
Hydralazine (Apresoline) 10-40 mg 10-20 minutes IV/IM
Methyldopa (Aldomet) 250 mg-1 g 2 hours IV
Trimethaphan (Arfonad) 3-6 mg/min 1-2 minutes IV
Phentolamine (Regitine) 0.1-2 mg/min 1 minute IV
Angiotension-Converting Enzyme Inhibitors
Captopril (Capoten) 25-400 mg/day in 2-3 doses 15-30 minutes PO
Enalapril/Enalaprilat (Vasotec/Vasotec IV) 2.5-4.0 mg/day 15 minutes PO/IV
Lisinopril (Zestril) 10-40 mg/day 1 hour PO
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5.1  Normal Chest X-Ray
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Normal chest x-ray film taken of a 28-year-old woman from 
a PA view. Some anatomic structures can be seen on the x-ray:
(A) diaphragm; (B) costophrenic angle; (C) left ventricle; (D) right
atrium; (E) aortic arch (referred to as aortic knob); (F) superior
vena cava; (G) trachea; (H) right bronchus (right hilum); (I) left
bronchus (left hilum); and (J) breast shadows.
5.2  Mediastinal Structures Visible on a Chest X-Ray
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(1) Trachea, (2) first rib, (3) superior vena cava, (4) aortic knob, (5) pul-
monary artery, (6) left main bronchus, (7) right main bronchus, (8) left
atrium, (9) right atrium, and (10) left ventricle. (From: Sanchez F. Funda-
mentals of chest x-ray interpretation. Crit Care Nurse. 1986;6[5]:53.)
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5.3  Chest X-Ray of COPD
COPD, flattened diaphragms, hyperinflation, widened intercostals
spaces, apical bullae, and chest rotation. (Reprinted from: Siela D.
Chest radiograph evaluation and interpretation. AACN Adv Crit Care.
2008;19:444-473.)
Bullae
Clavicle heads
Spinal pedicle
Trachea appears
deviated to left
L clavicle appears
longer in length
than R clavicle
Hyperinflation
Flattened diaphragms
Widened intercostal
spaces
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5.4  Chest X-Ray of Pneumothorax
Left pneumothorax, hyperlucency, and widened intercostals spaces.
(Reprinted from: Siela D. Chest radiograph evaluation and interpre-
tation. AACN Adv Crit Care. 2008;19:444-473.)
Slight mediastinal shift
Widened intercostal
spaces in left thorax
Hyperlucency
Lung
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5.5  Chest X-Ray of Right Lower Lobe Pneumonia
Right lower lobe pneumonia with minor fissure visualized.
(Reprinted from: Siela D. Chest radiograph evaluation and interpre-
tation. AACN Adv Crit Care. 2008;19:444-473.)
Minor fissure
Right heart border
visualized
Right lower lobe
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5.6  Chest X-Ray Showing Carina and Right Bronchus
Carina and right bronchus. (Reprinted from: Siela D. Chest radio-
graph evaluation and interpretation. AACN Adv Crit Care.
2008;19:444-473.)
R bronchus L bronchus
Carina
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5.7  Chest X-Ray with PA Catheter, ET Tube, and Chest Tube
Pulmonary artery catheter, endotracheal tube, and left chest tube.
(Reprinted from: Siela D. Chest radiograph evaluation and interpre-
tation. AACN Adv Crit Care. 2008;19:444-473.)
PAC
ET tube
ET tube tip
Chest
tube
PAC
PAC
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5.8  Acid-Base Abnormalities
Primary ABG Abnormalities ABG Changes with Compensation (if present)
Acid-Base Abnormality pH PaCO2 HCO3
 Respiratory (PaCO2) Metabolic (HCO3
)
Alkalemia
Metabolic ↑ ↑ ↑
Respiratory ↑ ↓ ↓
Acidemia
Metabolic ↓ ↓ ↓
Respiratory ↓ ↑ ↑
5.9  Indications for Mechanical Ventilation
Basic Physiologic Approximate Values Indicating Need for
Impairment Best Available Indicators Normal Range Ventilatory Support
Inadequate alveolar ventilation Paco2, mm Hg 36-44 Acute increase from normal or
(acute ventilatory failure) patient’s baseline
Arterial pH 7.36-7.44 7.25-7.30
Hypoxemia (acute oxygenation failure) Alveolar-to-arterial PO2 gradient 25-65 350
breathing 100% O2, mm Hg
Intrapulmonary right-to-left shunt 5 20-25
fraction, percentage
PaO2/FiO2, mm Hg 350-400 200
Inadequte lung expansion Tidal volume, mL/kg 5-8 4-5
Vital capacity 60-75 10
Respiratory rate, breaths/min (adults) 12-20 35
Inadequate respiratory muscle strength Maximum inspiratory pressure, cm H2O 80 to 100 20
Maximum voluntary ventilation, L/min 120-180 2  resting ventilatory 
requirement
Vital capacity, mL/kg 60-75 10-15
Excessive work of breathing Minute ventilation necessary to 5-10 15-20
maintain normal Paco2, L/min
Dead space ratio, percentage 0.25-0.40 0.60
Respiratory rate, breaths/min (adults) 12-20 35
Unstable ventilatory drive Breathing pattern; clinical setting
From: Luce J, Pierson D, eds. Critical Care Medicine. Philadelphia: WB Saunders; 1988:219.
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5.10  Pulmonary Specific Wean Criteria Thresholds
Traditional Weaning Criteria
• Negative inspiratory pressure (NIP)  −20 cm H2O
• Positive expiratory pressure (PEP)  +30 cm H2O
• Spontaneous tidal volume (SVT) 5 mL/kg
• Vital capacity (VC) 15 mL/kg
• Fraction of inspired oxygen (FiO2) 50%
• Minute ventilation (MV) 10 L/min
Integrated Weaning Criteria
• Index of rapid shallow breathing or frequency tidal volume ratio (fx/Vt) 105
5.11  Burns’ Wean Assessment Program (BWAP)a
I. General Assessment
Yes No Not Assessed
_____ _____ _____ 1. Hemodynamically stable (pulse rate, cardiac output)?
_____ _____ _____ 2. Free from factors that increase or decrease metabolic rate (seizures, temperature, sepsis, bacteremia,
hypo/hyperthyroid)?
_____ _____ _____ 3. Hematocrit 25% (or baseline)?
_____ _____ _____ 4. Systemically hydrated (weight at or near baseline, balanced intake and output)?
_____ _____ _____ 5. Nourished (albumin 2.5, parenteral/enteral feedings maximized)? *If albumin is low and anasarca or third
spacing is present, score for hydration should be “no.”
_____ _____ _____ 6. Electrolytes within normal limits (including Ca, Mg, PO4)? *Correct Ca
 for albumin level.
_____ _____ _____ 7. Pain controlled (subjective determination)?
_____ _____ _____ 8. Adequate sleep/rest (subjective determination)?
_____ _____ _____ 9. Appropriate level of anxiety and nervousness (subjective determination)?
_____ _____ _____ 10. Absence of bowel problems (diarrhea, constipation, ileus)?
_____ _____ _____ 11. Improved general body strength/endurance (ie, out of bed in chair, progressive activity program)?
_____ _____ _____ 12. Chest x-ray improving?
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5.11  Burns’ Wean Assessment Program (BWAP)a (continued )
II. Respiratory Assessment
Yes No Not Assessed
Gas Flow and Work of Breathing
_____ _____ _____ 13. Eupneic respiratory rate and pattern (spontaneous RR 25, without dyspnea, absence of accessory muscle
use)? *This is assessed off the ventilator while measuring #20-23.
_____ _____ _____ 14. Absence of adventitious breath sounds (rhonchi, rales, wheezing)?
_____ _____ _____ 15. Secretions thin and minimal?
_____ _____ _____ 16. Absence of neuromuscular disease/deformity?
_____ _____ _____ 17. Absence of abdominal distention/obesity/ascites?
_____ _____ _____ 18. Oral ETT  #7.5 or trach  #6.5?
Airway Clearance
_____ _____ _____ 19. Cough and swallow reflexes adequate?
Strength
_____ _____ _____ 20. NIP 20 (negative inspiratory pressure)?
_____ _____ _____ 21. PEP 30 (positive expiratory pressure)?
Endurance
_____ _____ _____ 22. STV 5 mL/kg (spontaneous tidal volume)?
_____ _____ _____ 23. VC 10-15 mL/kg (vital capacity)?
ABGs
_____ _____ _____ 24. pH 7.30-7.45?
_____ _____ _____ 25. PaCO2, 40 mm Hg (or baseline) with mV 10 L/min? *This is evaluated while on ventilator.
_____ _____ _____ 26. PaO2 60 on FiO2 40%?
aThe BWAP score is obtained by dividing the total number of BWAP factors scored as “yes” by 26. ©Burns 1990.
5.12  Algorithm for Management of Ventilator Alarms and/or Development of Acute
Respiratory Distress
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5.13  Algorithm to Correct Hypoxemia in an Acute COPD Patient
Algorithm to correct hypoxemia in an acute Ill COPD patient. ABG: arterial blood gas; NPPV: noninvasive positive pressure ventilation; O2: oxygen; PaCO2:
arterial carbon dioxide tension; PaO2: arterial oxygen tension; SaO2: arterial oxygen saturation. (From: American Thoracic Society and European Respira-
tory Society. Standards for the diagnosis and management of patients with COPD 2004;183. Available: http://www.thoracic.org/sections/copd/resources.
Accessed December 11, 2009.)
Assess patient,
obtain ABG,
begin oxygen
Assure PaO2 > 60 mmHg
Adjust O2 to SaO2 >90%
Hypercapnia?
(PaCO2 >50 mmHg)
No change in
oxygen setting
Reassess ABG
in 1-2 hours
Hypercapnia?
(PaCO2 >50 mmHg)
Maintain O2
SaO2 > 90%
pH <7.35?
(with PaO2 >60 mmHg)
Maintain O2
SaO2 >90%
Reassess ABG
in 2 hours
pH <7.35?
(with PaO2 >60 mmHg)
No change in
oxygen setting
Consider
mechanical ventilation,
NPPV, or intubation
No
No
Yes
Yes
Yes
Yes
Yes
No
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6.1  Glasgow Coma Scale
Behavior Scorea
Eye Opening (E)
Spontaneous 4
To verbal stimuli 3
To pain 2
None 1
Motor Response (M)
Obeys commands 6
Localizes pain 5
Withdraws to pain 4
Abnormal flexion 3
Extensor response 2
None 1
Verbal Response (V)
Oriented 5
Confused 4
Inappropriate words 3
Incomprehensible sounds 2
None 1
aComa score  E  M  V  (scores range from 3-15).
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6.2  Cranial Nerve Function
Nerve Function
I. Olfactory Sense of smell
II. Optic Visual fields, visual acuity
III. Oculomotor Most extraocular eye movements, ability to elevate eyelid, muscular contraction 
of the iris in response to light
IV. Trochlear Eye movement down and toward the nose
V. Trigeminal Facial sensation, including cornea, nasal mucosa, and oral mucosa; muscles 
of chewing and mastication
VI. Abducens Lateral eye movement
VII. Facial Facial muscles, including eyelid closure; taste in anterior two thirds of the tongue; secretion 
of saliva and tears
VIII. Acoustic Hearing and equilibrium
IX. Glossopharyngeal Gag reflex, muscles that control swallowing and phonation; taste in posterior third of tongue
X. Vagus (overlapping Salivary gland secretion; vagal control of heart,
innervation) lungs, and gastrointestinal tract
XI. Spinal accessory Sternocleidomastoid and trapezius muscle strength
XII. Hypoglossal Tongue movement
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6.3  Circle of Willis
Circle of willis
Anterior
communicating artery
Anterior cerebral artery
Internal carotid artery
Middle cerebral artery
Posterior
communicating artery
Cerebral artery
Basilar artery
Vertebral artery
The circle of Willis as seen from below the brain. (Reprinted from: Perry L, Sands JK. Vascular and degenerative problems of the brain. In: Phipps WJ, Marek JF, Mon-
ahan FD, Neighbors M, Sands JK, eds. Medical-Surgical Nursing: Health and Illness Perspectives. St Louis, MO: Mosby; 2003:1365.)
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6.4  Incomplete Spinal Cord Injury Syndromes
Sensory Function Below Level 
Syndrome Pathophysiolgy Motor Function Below Level of Injury of Injury
Central cord syndrome Injury to central gray matter with Weakness/paralysis of upper Sensory loss greater in upper 
preservation of outer white matter extremities greater than extremities than lower extremities
lower extremities
Anterior cord syndrome Injury to anterior portion of spinal Paralysis Loss of pain and temperature with 
cord, disruption of blood flow preservation vibration and position 
through anterior spinal artery sense
Posterior cord syndrome Injury to posterior column None Loss of vibration and position 
sense with preservation of pain 
and temperature sensation
Brown-Séquard syndrome Lateral injury to one side of the cord Ipsilateral motor paralysis Ipsilateral loss of vibration and 
position sense 
Contralateral loss of pain and 
temperature sensation
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6.5  Spinal Cord Injury–Functional Goals for Specific Levels 
of Complete Injury
Level Action/Muscles Tested Abilities Functional Goals
C1-C3 C3-limited movement of Breathing: Depends on a ventilator for breathing.
head and neck Communication: Talking is sometimes difficult, very limited or impossible. If 
ability to talk is limited, communication can be accomplished independently
with a mouth stick and assistive technologies like a computer for speech or
typing.
Effective verbal communication for the individual with SCI is essential to 
direct caregivers in the person’s daily activities, like bathing, dressing,
personal hygiene, transferring as well as bladder and bowel management.
Daily tasks: Assistive technology allow for independence in tasks such as
turning pages, using a telephone, and operating lights and appliances.
Mobility: Can operate an electric wheelchair by using a head control, mouth 
stick, or chin control. A power tilt wheelchair is also used for independent
pressure relief.
C3-C4 Usually has head and neck Breathing: May initially require a ventilator for breathing, usually adjust to 
control. Individuals at C4 breathing fulltime without ventilatory assistance.
level may shrug their Communication: Normal.
shoulders. Daily tasks: With specialized equipment, some may have limited independence
in feeding and independently operate an adjustable bed with an adapted
controller.
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6.5  Spinal Cord Injury–Functional Goals for Specific Levels of Complete Injury (continued )
Level Action/Muscles Tested Abilities Functional Goals
C5 Elbow flexors (biceps Typically has head and neck  Daily tasks: Independence with eating, drinking, face washing, brushing of 
brachii) control, can shrug shoulder  teeth, face shaving and hair care after assistance in setting up specialized 
and has shoulder control. equipment.
Can bend  his/her elbows Health care: Can manage their own health care by doing self-assist coughs 
and turn palms face up. and pressure reliefs by leaning forward or side to side.
Mobility: May have strength to push a manual wheelchair for short distances
over smooth surfaces. A power wheelchair with hand controls is typically
used for daily activities.
Driving may be possible after being evaluated by a qualified professional to
determine special equipment needs.
C6 Wrist extensors Has movement in head, neck, Daily tasks: With help of some specialized equipment, can perform with 
(extensor carpi shoulders, arms, and wrists.  greater ease and independence daily tasks of feeding, bathing, grooming, 
ulnaris, extensor Can shrug shoulders, bend   personal hygiene, and dressing. May independently perform light 
carpi radialis elbows, turn palms up and housekeeping duties.
longus and radialis down, and extend wrists. Health care: Can independently do pressure reliefs, skin checks, and turn in bed.
brevis) Mobility: Can independently do transfers but often require a sliding board.
Can use a manual wheelchair for daily activities but may use power 
wheelchair for greater independence.
150
6.5  Spinal Cord Injury–Functional Goals for Specific Levels of Complete Injury (continued )
Level Action/Muscles Tested Abilities Functional Goals
C7 Elbow extensors Has similar movement as an Daily tasks: Able to perform household duties. Need fewer adaptive aids in 
(triceps brachii) individual with C6, with independent living.
added ability to straighten Health care: Able to do wheelchair pushups for pressure reliefs.
his/her elbows. Mobility: Daily use of manual wheelchair. Can transfer with greater ease.
C8 Finger flexors (flexor Has added strength and Daily tasks: Can live independently without assistive devices in feeding, 
digitorum profundus- precision of fingers that bathing, grooming, oral and facial hygiene, dressing, bladder management, 
distal phalanx of the result in limited or natural and bowel management.
middle finger) hand function.
T1 Finger abductors
(abductor digiti
minimi)
T2-T6 Has normal motor function Mobility: Has increased ability to do some unsupported seated activities. 
in head, neck, shoulders, A few individuals are capable of limited walking with orthodic aids. This 
arms, hands, and requires extremely high energy and puts stress on the upper body, offering 
fingers. Has increased no functional advantage. Can lead to damage of upper joints.
use of rib and chest 
muscles,  or trunk control.
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6.5  Spinal Cord Injury–Functional Goals for Specific Levels of Complete Injury (continued )
Level Action/Muscles Tested Abilities Functional Goals
T7-L1 Has added motor function from Daily tasks: Able to perform unsupported seated activities.
increased abdominal control. Health care: Has improved cough effectiveness.
L2 Hip flexors (iliopsoas) Has additional return of motor Mobility: Walking can be a viable function, with the help of specialized leg 
movement in the hips and ankle braces. Lower levels walk with greater ease with the help of
and knees. assistive devices.
L3 Knee extensors 
(quadriceps femoris)
L4 Ankle dorsiflexors
(tibialis anterior)
L5 Long toe extensors
(hallucis longus)
S1-S5 Ankle plantar flexors Depending on level of injury, Mobility: Increased ability to walk with fewer or no supportive devices.
(gastrocnemius) there are various degrees 
of return of voluntary bladder, 
bowel and sexual functions.
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6.6  Intracranial Pressure Monitoring Systems
On the right, a ventriculostomy connects to a CSF collection system. A three-way stopcock allows either pressure monitoring or drainage of CSF. On the
left, a transducer is inserted into the brain parenchyma and anchored to the skull by a bolt mechanism. The transducer is attached to an external monitor-
ing device. (Reprinted from: Bergsneider M, Becker DP. Intracranial pressure monitoring. In: Shoemaker WC, Ayres SM, Grenvik A, Holbrook PR, eds. Text-
book of Critical Care. 3rd ed. Philadelphia, PA: WB Saunders;1995, p. 313.)
7Pharmacology Tables S e c t i o n
 7.1 Intravenous Medication
Administration Guidelines / 154
 7.2 Neuromuscular Blocking 
Agents / 179
 7.3 Vasoactive Agents / 182
 7.4 Antiarrhythmic Agents / 185
 7.5 Therapeutic Drug 
Monitoring / 191
 7.6 Tips for Calculating IV Medication
Infusion Rates / 194
PHARMACOLOGY TABLES
7.1  Intravenous Medication Administration Guidelines
Drug Usual IV Dose Rangea Standard Dilution Infusion Times/Comments/Drug Interactions
Abciximab
Bolus dose 0.25 mg/kg D5W in 250 mL Bolus infused over 10-60 minutes
Infusion dose 0.125 mcg/kg/min for 12 hours Maximum infusion rate  10 mcg/min
Acetazolamide 5 mg/kg/24h or 250 mg qd-qid Undiluted Infuse at 500 mg/min
Acyclovir 5 mg/kg q8h D5W 100 mL Infuse over at least 60 minutes
Adenosine 6 mg initially, then 12 mg 2 Undiluted Inject over 1-2 seconds
doses Drug interactions: theophylline (1); persantine (2)
Alteplase
Acute MI 100 mg over 3 hours 100 mg in NS 200 mL In acute MI infuse 10 mg over 2 minutes, then 50 mg over
PE 100 mg over 2 hours 1 hour, and then 40 mg over 2 hours.
Amikacin
Standard dose 7.5 mg/kg q12h D5W 50 mL Infuse over 30 minutes
Single daily dose 20 mg/kg q24h D5W 50 mL Drug interactions: neuromuscular blocking agents (3)
Therapeutic levels:
Peak: 20-40 mg/L; trough: 8 mg/L
Single daily dose: trough level at 24 hours  0 mg/L; peak 
levels unnecessary
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Aminophylline
Loading dose 6 mg/kg D5W 50 mL Infuse loading dose over 30 minutes
Maximum loading infusion rate 25 mg/min
Aminophylline  80% theophylline
Infusion dose 500 mg in D5W 500 mL Drug interactions: cimetidine, ciprofloxacin, erythromycin,
CHF 0.3 mg/kg/h clarithromycin (4)
Normal 0.6 mg/kg/h Therapeutic levels: 10-20 mg/L
Smoker 0.9 mg/kg/h
Ammonium chloride mEq Cl  Cl deficit (in mEq/L) 100 mEq in NS 500 mL Maximum infusion rate is 5 mL/min of a 0.2-mEq/mL 
 0.2  wt (kg) solution; correct 1/3 to 1/2 of Cl deficit while monitoring pH
and Cl; administer remainder as needed
Amphotericin B 0.5-1.5 mg/kg q24h D5W 250 mL Infuse over 2-6 hours
Do not mix in electrolyte solutions (eg, saline, lactated 
Ringer solution)
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7.1  Intravenous Medication Administration Guidelines (continued )
Drug Usual IV Dose Rangea Standard Dilution Infusion Times/Comments/Drug Interactions
a Usual dose ranges are listed; refer to appropriate disease state for specific dose.
Abbreviations: bid, twice a day; HF, heart failure; conc, concentration; D5W, destrose-5%-water; DVT, deep venous thrombosis; HPLC, high-performance liq-
uid chromatography; IM, intramuscular; IV, intravenous; IVP, IV push; IVPB, IV piggyback; MI, myocardial infarction; NS, normal saline; NSAID, nonsteroidal
anti-inflammatory drug; PCP, Pneumocystis carinii pneumonia; PE, pulmonary embolism; PO, orally; prn, as needed; qd, daily; SW, sterile water.
Drug interactions: (1) antagonizes adenosine effect; (2) potentiates adenosine effect; (3) potentiates effect of neuromuscular blocking agents; (4) inhibits theo-
phylline metabolism; (5) antagonizes effect of neuromuscular blocking agents: (6) metabolism inhibited by cimetidine; (7) metabolism inhibited by ciprofloxacin;
(8) increased digoxin concentrations; (9) metabolism inhibited by erythromycin; (10) increased nephrotoxicity; (11) increased heparin requirements.
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Ampicillin 0.5-3 g q4-6h NS 100 mL Infuse over 15-30 minutes
Ampicillin/sulbactam 1.5-3 g q6h NS 100 mL Infuse over 15-30 minutes
Anistreplase (APSAC) 30 U IV SW 5 mL Infuse over 5 minutes, give with aspirin 325 mg PO 
immediately
Preparation should be discarded if not used within 6 hours
Argatroban
Bolus dose 350 mcg/kg 250 mg in NS 250 mL Titrate to aPTT or ACT
Infusion dose 25 mcg/kg/min
Atenolol 5 mg IV over 5 minutes, 5 mg IV Undiluted Inject 1 mg/min
10 minutes later
Atracurium
Intubating dose 0.4-0.5 mg/kg Undiluted Inject over 60 sec to prevent histamine release
Maintenance dose 0.08-0.1 mg/kg Undiluted Inject over 60 sec to prevent histamine release
Infusion dose 5-9 mcg/kg/min 1000 mg in D5W 150 mL Continuous infusion. Final volume  250 mL, conc 
4 mg/mL
Drug interactions: aminoglycosides (3); anticonvulsants (5)
Aztreonam 0.5-2 g q6-12h D5W 100 mL Infuse over 15-30 minutes
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Bivalirudin
Bolus dose 1 mg/kg 250 mg in D5W 500 mL Infuse bolus over 2 min
Infusion dose 2.5 mg/kg/h 4 hours; if necessary Titrate to aPTT or ACT
0.2 mg/kg/h for up to 20 hours
Bumetanide
Bolus dose 0.5-1 mg Undiluted Maximum injection rate: 1 mg/min
Infusion dose 0.08-0.3 mg/h 2.4 mg in NS 100 mL Continuous infusion
Calcium (elemental) 100-200 mg of elemental 1000 mg in NS 1000 mL Ca chloride 1 g  272 mg (13.6 mEq) of elemental calcium
calcium IV over 15 minutes Ca gluconate 1 g  90 mg (4.65 mEq) of elemental calcium
followed by 100 mg/h
Cefazolin 0.5-1 g q6-8h D5W 50 mL Infuse over 15-30 minutes
Cefepime 1-2 g q8-12h 1-2 g in D5W 100 mL Infuse over 15 minutes
Cefonicid 1-2 g q24h D5W 50 mL Infuse over 15-30 minutes
Cefoperazone 1-2 g q12h D5W 50 mL Infuse over 15-30 minutes
Cefotaxime 1-2  g q4-6h D5W 50 mL Infuse over 15-30 minutes
Cefotetan 1-2 g q12h D5W 50 mL Infuse over 15-30 minutes
Cefoxitin 1-2 g q4-6h D5W 50 mL Infuse over 15-30 minutes
Ceftazidime 0.5-2 g q8-12h D5W 50 mL Infuse over 15-30 minutes
Ceftizoxime 1-2 g q8-12h D5W 50 mL Infuse over 15-30 minutes
Ceftriaxone 0.5-2 g q12-24h D5W 50 mL Infuse over 15-30 minutes
Cefuroxime 0.75-1.5 g q8h D5W 50 mL Infuse over 15-30 minutes
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Chlorothiazide 0.5-1 g qd-bid SW 18 mL Inject over 3-5 minutes
Chlorpromazine 10-50 mg q4-6h Dilute with NS to a final Inject at 1 mg/minutes
concentration of
1 mg/mL
Cimetidine
IVPB 300 mg q6-8h D5W 50 mL Infuse over 15-30 minutes 
IVP dose may be injected over at least 5 minutes
Infusion dose 37.5 mg/h D5W 250 mL Continuous infusion
Drug interactions: theophylline, warfarin, phenytoin, 
lidocaine, benzodiazepines (6)
Ciprofloxacin 200-400 mg q8-12h Premix solution 2 mg/mL Infuse over 60 minutes
Drug interactions: theophylline, warfarin (7)
Cisatricurium
Infusion dose 1-3 mcg/kg/min
Clevidipine 1-16 mg/h Undiluted Continuous infusion
Clindamycin 150-900 mg q8h D5W 250 mL Infuse over 30-60 minutes
Conivaptan
Bolus dose 20 mg D5W 100 mL Infuse over 30 minutes
Infusion dose 20 mg D5W 250 mL Infuse over 24 hours
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Conjugated 0.6 mg/kg/d 5 days NS 50 mL Infuse over 15-30 minutes
estrogens
Cosyntropin 0.25 mg IV Undiluted Inject over 60 seconds
Cyclosporine 5-6 mg/kg q24h D5W 100 mL Infuse over 2-6 hours
Drug interactions: digoxin (8); erythromycin (9); amphotericin,
NSAID (10)
IV dose  1/3 PO dose
Therapeutic levels: trough: 50-150 ng/mL (whole 
blood—HPLC)
Dantrolene
Bolus dose 1-2 mg/kg SW 60 mL Administer as rapidly as possible
Maximum dose 10 mg/kg Do not dilute in dextrose or electrolyte-containing solutions
Maintenance dose 2.5 mg/kg q4h 24h SW 60 mL Infuse over 60 minutes
Daptomycin 4-6 mg/kg q24h 250 or 500 mg in Infuse over 30 minutes
NS 50 mL
Desmopressin 0.3 mg/kg NS 50 mL Infuse over 15-30 minutes
Dexamethasone 0.5-20 mg NS 50 mL May give doses 10 mg undiluted IVP over 60 seconds
Dexmedetomidine
Bolus dose 1 mcg/kg 200 mcg in NS 50 mL Infuse bolus over 10 minutes
Infusion dose 0.2-1 mcg/kg/h
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Diazepam 2.5-5 mg q2-4h Undiluted Inject 2-5 mg/minutes
Active metabolites contribute to activity
Diazoxide 50-150 mg q5-15 min Undiluted Inject over 30 seconds
Maximum 150 mg/dose
Digoxin
Digitalizing dose 0.25 mg q4-6h up to 1 mg Undiluted Inject over 3-5 min
Maintenance dose 0.125-0.25 mg q24h Drug interactions: amiodarone, cyclosporine, quinidine, 
verapamil (8)
Therapeutic levels: 0.5-2.0 ng/mL
Diltiazem
Bolus dose 0.25-0.35 mg/kg Undiluted Inject over 2 minutes
Infusion dose 5-15 mg/h 125 mg in D5W 100 mL Continuous infusion (final conc  1 mg/mL)
Diphenhydramine 25-100 mg IV q 2-4h Undiluted Inject over 3-5 minutes
Competitive histamine antagonist, doses 1000 mg/
24 h may be required in some instances
Dobutamine 2.5-20 mcg/kg/min 500 mg in D5W 250 mL Continuous infusion
Dolasetron 1.8 mg/kg or 100 mg Undiluted or 100 mg in Infuse undiluted drug over at least 30 seconds
D6W 50 mL Infuse piggyback over 15 minutes
Administer 30 L, minutes prior to chemo or 1 hour prior to 
anesthesia
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Dopamine
Renal dose 5 mcg/kg/min 400 mg in D5W 250 mL Continuous infusion
Inotrope 5-10 mcg/kg/min 400 mg in D5W 250 mL Continuous infusion
Pressor 10 mcg/kg/min 400 mg in D5W 250 mL Continuous infusion
Doripenem 500 mg q-8h D5W or NS 100 mL Infuse over 60 minutes-4 hours
Doxacurium
Intubating dose 0.025-0.08 mg/kg Undiluted Inject over 5-10 seconds
Maintenance dose 0.005-0.01 mg/kg Undiluted Inject over 5-10 seconds
Infusion dose 0.25 mcg/kg/min 25 mg in D5W 50 mL Continuous infusion
Dose based on lean body weight
Drug interactions: aminoglycosides (3); anticonvulsants (5)
Doxycycline 100-200 mg q12-24h D5W 250 mL Infuse over 60 minutes
Drotrecogin alfa 24 mcg/kg/h 100 or 200 mcg/mL Infuse through dedicated line or lumen 
dilution in NS (multilumen catheter).
Total infusion time is 96 hours
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anti-inflammatory drug; PCP, Pneumocystis carinii pneumonia; PE, pulmonary embolism; PO, orally; prn, as needed; qd, daily; SW, sterile water.
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phylline metabolism; (5) antagonizes effect of neuromuscular blocking agents: (6) metabolism inhibited by cimetidine; (7) metabolism inhibited by ciprofloxacin;
(8) increased digoxin concentrations; (9) metabolism inhibited by erythromycin; (10) increased nephrotoxicity; (11) increased heparin requirements.
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Droperidol 0.625-10 mg q1-4h Undiluted Inject over 3-5 minutes
Enalaprilat 0.625-1.25 mg q6h Undiluted Inject over 5 minutes
Initial dose for patients on diuretics is 0.625 mg
Epinephrine 1-4 mcg/min 1 mg in D5W 250 mL Continuous infusion
Eptifibatide
Bolus dose 180 mcg/kg Undiluted Maximum infusion duration of 72 hours
Infusion dose 2 mcg/kg/min until discharge or 
CABG
Ertapenem 1 g q24h 1 g in NS 50 mL Infuse over 30 minutes
Erythromycin 0.5-1 g q6h NS 250 mL Infuse over 60 minutes
Drug interactions: theophylline (4); cyclosporine (9)
Erythropoietin 12.5-600 U/kg 1-3 per week Undiluted Inject over 3-5 minutes
Esmolol
Bolus dose 500 mcg/kg Undiluted Inject over 60 seconds
Infusion dose 50-400 mcg/kg/min 5 g in D5W 500 mL Continuous infusion
Ethacrynic acid 50 mg D5W 50 mL Inject over 3-5 minutes
May repeat 1 Maximum single dose 100 mg
Etidronate 7.5 mg/kg qd 3 days NS or D5W 500 mL Infuse over at least 2 hours
Famotidine 20 mg q12h D5W 100 mL Infuse over 15-30 minutes
Fenoldopam
Infusion dose 0.1-1.6 mcg/kg/min 20 mg in D5W 250 mL Titrate to BP
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Fentanyl
Bolus dose 25-75 mcg q1-2h Undiluted Inject over 5-10 seconds
Infusion dose 50-100 mcg/h Undiluted Continuous infusion
Filgastrim 1-20 mcg/kg 2-4 weeks D5W Preferred route of administration is subcutaneous
Fluconazole 100-800 mg q24h Premix solution 2 mg/mL Maximum infusion rate 200 mg/h (IV rate is 15-30 minutes)
Flumazenil
Reversal of conscious 0.2 mg initially, then Undiluted Inject over 15 seconds
sedation 0.2 mg q60 sec to a Maximum dose of 3 mg in any 1-hour period
total of 1 mg
Benzodiazepine 0.2 mg initially, then 0.3 Undiluted Inject over 30 seconds
overdose mg 1 dose, then 0.5 Maximum dose of 3 mg in any 1-hour period
mg q30s up to a
total of 3 mg
Continuous infusion 0.1-0.5 mg/h 5 mg in D5W 1000 mL Continuous infusion
Foscarnet
Induction dose 60 mg/kg q8h Undiluted Infuse over 1 hour
Maintenance dose 90-120 mg/kg q24h Undiluted Infuse over 2 hours
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Fosphenytoin NS 250 mL Infuse no faster than 150 mg/min
Status epilepticus
Loading dose 15-20 mg/kg
Nonemergency
Loading dose 10-20 mg/kg
Maintenance dose 4-6 mg/kg/day
Furosemide
Bolus dose 10-100 mg q1-6h Undiluted Maximum injection rate 40 mg/min
Infusion dose 1-15 mg/h 100 mg in NS 100 mL Continuous infusion
Gallium nitrate 100-200 mg/m2 qd 5 days D5W 1000 mL Infuse over 24 hours
Ganciclovir 2.5 mg/kg q12h D5W 100 mL Infuse over 1 hour
Gentamicin
Loading dose 2-3 mg/kg D5W 50 mL Infuse over 30 minutes
Maintenance dose 1.5-2.5 mg/kg q8-24h D5W 50 mL Infuse over 30 minutes
Single daily dose 5-7 mg/kg q24h D5W 50 mL Infuse over 30 minutes
Critically ill patients have an increased volume of distribution 
requiring increased doses
Drug interactions: neuromuscular blocking agents
Therapeutic levels:
Peak: 4-10 mg/L
Trough: 2 mg/L
Single daily dose: trough level at 24 hours  0 mg/L;
peak levels unnecessary
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Glycopyrrolate 5-15 mcg/kg Undiluted Inject over 60 seconds
Granisetron 10 mcg/kg D5W 50 mL Infuse over 15 minutes
Haloperidol (lactate)
Bolus dose 1-10 mg q2-4h Undiluted Inject over 3-5 minutes
Infusion dose 10 mg/h 100 mg in D5W 100 mL Continuous infusion
In urgent situations the dose may be doubled every 
20-30 minutes until an effect is obtained
Decanoate salt is only for IM administration
Heparin 10-25 U/kg/h 25,000 U in D5W 500 mL Drug interactions: nitroglycerin (11)
Hydralazine 10-25 mg q2-4h Undiluted
Hydrochloric acid mEq  (0.5  BW  100 mEq in SW 1000 mL Maximum infusion rate  0.2 mEq/kg/h
(103  serum Cl))
Hydrocortisone 12.5-100 mg q6-12h Undiluted Inject over 60 seconds
Hydromorphone 0.5-2 mg q4-6h Undiluted Inject over 60 seconds
Dilaudid-HP available as 10 mg/mL
Ibutilide Infuse over 10 minutes
Patient 60 kg 1 mg NS 50 mL Repeat dose possible 10 minutes after completion of initial bolus
Patient 60 kg 0.01 mg/kg
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Inamrinone
Loading dose 0.75-3 mg/kg Undiluted Inject over 1-2 minutes
Do not mix in dextrose-containing solutions; may be injected 
into running dextrose infusions through a Y-connector or 
directly into tubing
Infusion dose 5-20 mcg/kg/min 300 mg in NS 120 mL
Imipenem 0.5-1 g q6-8h D5W 100 mL Infuse over 30-60 minutes
Isoproterenol 1-10 mcg/min 2 mg in D5W 500 mL Continuous infusion
Ketamine
Bolus dose 1-4.5 mg/kg Undiluted Inject over 60 seconds
Infusion dose 5-45 mcg/kg/min 200 mg in D5W 500 mL Continuous infusion
Labetalol
Bolus dose 20 mg, then double q10min Undiluted Inject over 2 minutes
(maximum total dose of 300 mg)
Infusion dose 1-4 mg/min 200 mg in D5W 160 mL Continuous infusion
Lepirudin
Bolus dose 0.4 mg/kg 100 mg in D5W 50 mL Titrated to aPTT, 12-hour expiration once compounded
Infusion dose 0.15 mg/kg/h for 2-10 days
Levofloxacin 250-750 mg q24-48h D5W 50-150 mL Infuse over 60 minutes (250 mg, 500 mg)
Infuse over 90 minutes (750 mg)
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Levothyroxine 25-200 mg q24h Undiluted Inject over 5-10 second
IV dose  75% of PO dose
Lidocaine
Bolus dose 1 mg/kg Undiluted Inject over 60 seconds
Infusion dose 1-4 mg/min 2 g in D5W 500 mL Continuous infusion
Drug interactions: cimetidine (6)
Therapeutic levels: 1.5-5.0 mg/L
Linezolid 600 mg q12h 600 mg in D5W 300 mL Infuse over 30-120 minutes
Linezolid may exhibit a yellow color that can intensify 
over time without adversely affecting potency
Lorazepam
Bolus dose 0.5-2 mg q1-4h Dilute 1:1 with NS before Inject 2 mg/minutes
administration
Infusion dose 0.06 mg/kg/h 20 mg in D5W 250 mL Monitor for lorazepam precipitate in solution
Use in-line filter during continuous infusion to avoid 
infusing precipitate into patient
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anti-inflammatory drug; PCP, Pneumocystis carinii pneumonia; PE, pulmonary embolism; PO, orally; prn, as needed; qd, daily; SW, sterile water.
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phylline metabolism; (5) antagonizes effect of neuromuscular blocking agents: (6) metabolism inhibited by cimetidine; (7) metabolism inhibited by ciprofloxacin;
(8) increased digoxin concentrations; (9) metabolism inhibited by erythromycin; (10) increased nephrotoxicity; (11) increased heparin requirements.
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Magnesium (elemental) Magnesium1 g  8 mEq
Magnesium 25 mEq over 24 hours followed 25 mEq in D5W 1000 mL Continuous infusion
deficiency by 6 mEq over the next
12 hours
Acute myocardial 15-45 mEq over 24-48 25 mEq  in D5W 1000 mL Continuous infusion
infarction hours followed by 12.5 mEq/day
for 3 days
Ventricular 16 mEq over 1 hour followed by 40 mEq in D5W 1000 mL 16 mEq (2 g) may be diluted in 100 mL
arrythmias 40 mEq over 6 hours D5W and infused over 1 hour
Mannitol
Diuretic Undiluted Inject over 30-60 minutes
Bolus dose 0.25-0.5 g/kg
Maintenance dose 0.25-0.5 g/kg q4h
Cerebral edema 1.5-2 g/kg over 30-60 minutes
Meperidine 25-100 mg q2-4h Undiluted Inject over 60 seconds
Avoid in renal failure
Meropenem 0.5-2 g q8-24h NS 50 mL or undiluted Infuse over 15-30 min or bolus dose over 3-5 minutes
Methadone 5-20 mg qd Undiluted Inject over 3-5 minutes
Accumulation with repetitive dosing
Methyldopate 0.25-1 g q6h D5W 100 mL Infuse over 30-60 minutes
Methylprednisolone 10-500 mg q6h Undiluted Inject over 60 seconds
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Metoclopramide
Small intestine 10 mg  1 Undiluted Inject over 3-5 minutes
intubation
Antiemetic 2 mg/kg before chemo, D5W 50 mL Infuse over 15-30 minutes
then 2 mg/kg q2h 2,
then q3h 3
Metoprolol 5 mg q2min 3 Undiluted Inject over 3-5 min
Metronidazole 500 mg q6h Premix solution 5 mg/mL Infuse over 30 minutes
Midazolam
Bolus dose 0.025-0.35 mg/kg q1-2h Undiluted Inject 0.5 mg/min
Infusion dose 0.5-5 mcg/kg/min 50 mg in D5W 100 mL Continuous infusion
Unpredictable clearance in critically ill patients
Drug interactions: cimetidine (6)
Milrinone
Loading dose 50 mcg/kg 1 mg/mL Infuse over 10 min
Available in 5-mL syringe
Maintenance dose 0.375-0.75 mcg/kg/min 50 mg in D5W 250 mL Continuous infusion
Mivacurium
Intubating dose 0.25 mg/kg Undiluted Inject over 60 seconds
Maintenance dose 0.1 mg/kg Undiluted Inject over 60 seconds
Infusion dose 9-10 mcg/kg/min 50 mg in D5W 100 mL Continuous infusion
Drug interactions: aminoglycosides (3); anticonvulsants (5)
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Morphine
Bolus dose 2-10 mg Undiluted Inject over 60 seconds
Infusion dose 2-5 mg/h 100 mg in D5W 100 mL Continuous infusion
Moxifloxacin 400 mg q24h 400 mg in NS 250 mL Infuse over 60 minutes
Nafcillin 0.5-2 g q4-6h D5W 100 mL Infuse over 30-60 minutes
Naloxone
Postoperative opiate
depression
Loading dose 0.1-0.2 mg q2-3min Undiluted Infuse over 60 minutes
Infusion dose 3-5 mcg/kg/h 2 mg in D5W 250 mL Continuous infusion
Opiate overdose
Loading dose 0.4-2 mg q2-3min Undiluted Infuse over 60 seconds
Infusion dose 2.5-5 mcg/kg/h 2 mg in D5W 250 mL Continuous infusion
Neostigmine 25-75 mcg/kg Undiluted Inject over 60 seconds
Nesiritide
Bolus dose 2 mcg/kg 1.5 mg in Monitor for hypotension
preservative-free
Infusion dose 0.01 mcg/kg/min D5W 250 mL
Nitroglycerin 10-300 mcg/min 50 mg in D5W 250 mL Continuous infusion
Drug interactions: heparin (11)
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Nitroprusside 0.5-10 mcg/kg/min 50 mg in D5W 250 mL Continuous infusion
Maintain thiocyanate 10 mg/dL
Norepinephrine 4-10 mcg/min 4 mg in D5W 250 mL Continuous infusion
Ofloxacin 200-400 mg q12h D5W 100 mL Infuse over 60 minutes
Ondansetron
Chemotherapy- 32 mg 30 min before D5W 50 mL Infuse over 15-30 minutes
induced nausea chemotherapy
and vomiting
Postoperative nausea 4 mg 1 dose Undiluted Inject over 2-5 minutes
and vomiting
Oxacillin 0.5-2 g q4-6h D5W 100 mL Infuse over 30 minutes
Pamidronate 60-90 mg 1 dose D5W 1000 mL Infuse over 24 hours
Pancuronium
Intubating dose 0.06-0.1 mg/kg Undiluted Inject over 60 seconds
Maintenance dose 0.01-0.015 mg/kg Undiluted Inject over 60 seconds
Infusion dose 1 mcg/kg/min 50 mg in D5W 250 mL Continuous infusion
Metabolite contributes to activity
Drug interactions: aminoglycosides (3); anticonvulsants (5)
Penicillin G 8-24 MU divided q4h D5W 100 mL Infuse over 15-30 minutes
Pentamidine 4 mg/kg q24h D5W 50 mL Infuse over 60 minutes
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Pentobarbital
Bolus dose 5-10 mg/kg NS 100 mL Infuse over 2 hours
Infusion dose 0.5-1 mg/kg/h initially, then NS 250 mL Continuous infusion
0.5-4 mg/kg/h 2 g in NS 250 mL Therapeutic levels: 20-50 mg/L
Phenobarbital NS 100 mL Infuse over 2 hours
Bolus dose 5-10 mg/kg NS 250 mL Continuous infusion
Infusion dose 0.5-1 mg/kg/h initially, then 2 g in NS 250 mL Therapeutic levels: 20-50 mg/L
0.5-4 mg/kg/h
Phentolamine
Bolus dose 2.5-10 mg prn q5-15min Undiluted Inject over 3-5 minutes
Continuous infusion 1-10 mg/min 50 mg in D5W 100 mL Continuous infusion
Phenylephrine 20-30 mcg/min 15 mg in D5W 250 mL Continuous infusion; 0.5 mg over 20-30 seconds
Phenytoin Maximum infusion rate is 50 mg/min
Status epilepticus Undiluted Drug interactions: cimetidine; neuromuscular blocking agents
Bolus dose 15-20 mg/kg Therapeutic levels: 10-20 mg/L
Infusion dose 5 mg/kg/day (divided into 2 or 
3 doses)
Phosphate (potassium) 0.08-0.64 mmol/kg Function of K Infuse over 6-8 hours
concentration 1 mmol of PO4  P 31 mg
Solution should be made no more concentrated than 
0.4 mEq/mL K
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Piperacillin 2-4 g q4-6h D5W 100 mL Infuse over 15-30 minutes
Piperacillin/tazobactam 3.375 g IV q6h D5W 100 mL Infuse over 30 minutes
Each 2.25-g vial contains 2 g piperacillin and 0.25 g 
tazobactam
Potassium chloride 5-40 mEq/h 40 mEq in 1000 mL Cardiac monitoring should be used with infusion rates 
(NS, D5W, etc) 20 mEq/h
Prednisolone 4-60 mg q24h Undiluted Inject over 60 seconds
Procainamide
Loading dose 15 mg/kg D5W 50 mL Maximum infusion rate 25-50 mg/min
Infusion dose 1-4 mg/min 2 g in D5W 500 mL Continuous infusion
Therapeutic levels:
Procainamide: 4-10 mg/L
NAPA: 10-20 mg/L
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uid chromatography; IM, intramuscular; IV, intravenous; IVP, IV push; IVPB, IV piggyback; MI, myocardial infarction; NS, normal saline; NSAID, nonsteroidal anti-
inflammatory drug; PCP, Pneumocystis carinii pneumonia; PE, pulmonary embolism; PO, orally; prn, as needed; qd, daily; SW, sterile water.
Drug interactions: (1) antagonizes adenosine effect; (2) potentiates adenosine effect; (3) potentiates effect of neuromuscular blocking agents; (4) inhibits theo-
phylline metabolism; (5) antagonizes effect of neuromuscular blocking agents: (6) metabolism inhibited by cimetidine; (7) metabolism inhibited by ciprofloxacin;
(8) increased digoxin concentrations; (9) metabolism inhibited by erythromycin; (10) increased nephrotoxicity; (11) increased heparin requirements.
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Propofol
Bolus dose 0.25-0.5 mg/kg Undiluted Infuse over 1-2 minutes
Infusion dose 5-50 mcg/kg/min Undiluted Continuous infusion
Propranolol
Bolus dose 0.5-1 mg q5-15min Undiluted Infuse over 60 seconds
Infusion dose 1-4 mg/h 50 mg in D5W 500 mL Continuous infusion
Protamine 30 min: 1-1.5 U 50 mg in SW 5 mL Inject over 3-5 minutes; do not exceed 50 mg in 10 minutes
mg/100 U; 30-60 minutes:
0.5-0.75 mg/100 U; 120 min:
0.25-0.375 mg/100 U
Pyridostigmine 100-300 mcg/kg Undiluted Use to reverse long-acting neuromuscular blocking agents
Inject over 60 seconds
Quinidine gluconate 600 mg initially, then 400 800 mg in D5W 50 mL Infusion rate 1 mg/min; use cardiac monitor
mg q2h, maintenance Therapeutic levels: 1.5-5 mg/L
200-300 mg q6h
Quinupristin/dalfopristin 7.5 mg/kg q8-12h D5W 250 mL Infuse over 60 minutes
Central line preferred
Flush with D5W after peripheral infusion to minimize venous 
irritation
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Ranitidine
IVPB 50 mg q6-8h D5W 50 mL Infuse over 15-30 minutes
IVP dose should be injected over at least 5 minutes
Infusion dose 6.25 mg/h 150 mg in D5W 150 mL Continuous infusion
Reteplase 10-U bolus  2 SW 10 mL Inject over 2 minutes, use dedicated IV line, flush 
heparin-coated catheters with NS D5W after use
Rocuronium
Intubating dose 0.45-1.2 mg/kg Undiluted Inject over 60 seconds
Maintenance dose 0.075-0.15 mg/kg Undiluted Inject over 60 seconds
Infusion dose 10-14 mcg/kg/min 50 mg in D5W 100 mL Continuous infusion
Streptokinase
Acute MI 1.5 MU D5W 45 mL Infuse over 30 minutes
DVT, PE 250,000 U over 30 minutes, D5W 90 mL Continuous infusion
then 100,000 U/h
over 24-72 hours
Succinylcholine 0.6-2 mg/kg Undiluted Inject over 60 seconds
Tacrolimus 50-100 mcg/kg/day 5 mg in D5W 250 mL
Tenecteplase 30-50 mg SW 10 mL Inject over 5 seconds
t-PA 100 mg 100 mg in D5W 100 mL Infuse 60 mg/h during first hour, then 20 mg/h for 2 hours
Theophylline Smokers: 0.9 mg/kg/h
Bolus dose 6 mg/kg 800 mg in 500 mL Nonsmokers: 0.6 mg/kg/h
Infusion dose 0.3-0.9 mg/kg/h premixed Liver and heart failure: 0.3 mg/kg/h
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Thiamine 100 mg qd  3 D5W 50 mL Infuse over 15-30 minutes
Thiopental 3-4 mg/kg Undiluted Inject over 3-5 minutes
Ticarcillin 3 g q3-6h D5W 100 mL Infuse over 15-30 minutes
Ticarcillin/clavulanate 3.1 g q4-6h D5W 100 mL Infuse over 15-30 minutes
Tirofiban
Bolus dose 0.4 mcg/kg/h 25 mg in D5W 500 mL Bolus infused over 30 minutes
Infusion dose 0.1 mcg/kg/min for 12-24 hours 
after angioplasty or arthrectomy
Tobramycin
Loading dose 2-3 mg/kg D5W 50 mL Infuse over 30 minutes
Maintenance dose 1.5-2.5 mg/kg q8-24h D5W 50 mL Infuse over 30 minutes
Critically ill patients have an increased volume of distribution 
requiring increased doses
Drug interactions: neuromuscular blocking agents (3)
Therapeutic levels
Peak: 4-10 mg/L
Trough: 2 mg/L
Torsemide 5-20 mg qd Undiluted Inject over 60 seconds
Trimethaphan 0.5-5 mg/min 500 mg in D5W 500 mL Continuous infusion
7.1  Intravenous Medication Administration Guidelines (continued )
Drug Usual IV Dose Rangea Standard Dilution Infusion Times/Comments/Drug Interactions
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Trimethaprim-
sulfamethoxazole
Common infections 4-5 mg/kg q12h TMP 16 mg-SMX 80 mg Infuse over 60 minutes
per D5W 25 mL
PCP 5 mg/kg q6h TMP 16 mg-SMX 80 mg Infuse over 60 minutes
per D5W 25 mL Therapeutic levels: 100-150 mg/L
Urokinase 4400 U/kg over 10 minutes, D5W 195 mL Continuous infusion
Pulmonary then 4400 U/h
embolism over 12 hours
Vancomycin 1 g q12h D5W 250 mL Infuse over at least 1 hour to avoid “red-man” syndrome
Therapeutic levels
Peak: 20-40 mg/L
Trough: 10 mg/L
Vasopressin
GI hemorrhage 0.2-0.3 U/min 100 U in D5W 250 mL Maximum infusion rate 0.9 U/min
Septic shock 0.01-0.04 U/min
7.1  Intravenous Medication Administration Guidelines (continued )
Drug Usual IV Dose Rangea Standard Dilution Infusion Times/Comments/Drug Interactions
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Vecuronium
Intubating dose 0.1-0.28 mg/kg Undiluted Inject over 60 seconds
Maintenance dose 0.01-0.015 mg/kg Undiluted Inject over 60 seconds
Infusion dose 1 mcg/kg/min 20 mg in D5W 100 mL Continuous infusion
Metabolite contributes to activity
Drug interactions: aminoglycosides (3); 
anticonvulsants (5)
Verapamil
Bolus dose 0.075-0.15 mg/kg Undiluted Inject over 1-2 minutes
Continuous infusion
Drug interactions:
digoxin (8)
a Usual dose ranges are listed; refer to appropriate disease state for specific dose.
Abbreviations: bid, twice a day; HF, heart failure; conc, concentration; D5W, destrose-5%-water; DVT, deep venous thrombosis; HPLC, high-performance liq-
uid chromatography; IM, intramuscular; IV, intravenous; IVP, IV push; IVPB, IV piggyback; MI, myocardial infarction; NS, normal saline; NSAID, nonsteroidal
anti-inflammatory drug; PCP, Pneumocystis carinii pneumonia; PE, pulmonary embolism; PO, orally; prn, as needed; qd, daily; SW, sterile water.
Drug interactions: (1) antagonizes adenosine effect; (2) potentiates adenosine effect; (3) potentiates effect of neuromuscular blocking agents; (4) inhibits theo-
phylline metabolism; (5) antagonizes effect of neuromuscular blocking agents: (6) metabolism inhibited by cimetidine; (7) metabolism inhibited by ciprofloxacin;
(8) increased digoxin concentrations; (9) metabolism inhibited by erythromycin; (10) increased nephrotoxicity; (11) increased heparin requirements.
7.1  Intravenous Medication Administration Guidelines (continued )
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7.2  Neuromuscular Blocking Agents
Agent Dose Onset/Duration Comments
Depolarizing Agents
Succinylcholine Intubating dose: Onset: 1 minutes Prolonged paralysis in pseudocholinesterase deficiencies
1-2 mg/kg Duration: 10 minutes Contraindications: Family history of malignant hyperthermia, 
neuromuscular disease, hyperkalemia, open eye injury, major
tissue injury (burns, trauma, crush), increased intracranial
pressure
Side effects: bradycardia (especially in children), tachycardia,
increased serum potassium concentration
Nondepolarizing Agents
Short-Acting
Mivacurium Intubating dose: Onset: 5 minutes Metabolized by pseudocholinesterase
0.25 mg/kg Duration: 15-20 minutes Intubating dose: initial 0.15 mg/kg 
followed in 30 seconds by 0.1 mg/kg
Maintenance dose: Duration: 15 minutes
0.1 mg/kg
Continuous infusion:
9.0-10.0 mcg/kg/min
180
Intermediate-Acting
Atracurium Intubating dose: Onset: 2 minutes Histamine release with bolus doses 0.6 mg/kg and may
0.5 mg/kg Duration: 30-40 minutes precipitate asthma or hypotension
Maintenance dose: Duration: 15-25 minutes Elimination independent of renal hepatic function
0.08-0.10 mg/kg Metabolized in the plasma by Hofmann elimination and ester
Continuous infusion: hydrolysis
5-9 mcg/kg/min Duration not prolonged by renal or liver failure
Used when succinylcholine is contraindicated or not preferred
Cisatricurium Intubating dose: Onset: 2 minutes Decreased histamine release compared to atracurium
0.15-0.2 mg/kg Duration: 30-90 minutes Elimination independent of renal or hepatic function
Maintenance dose: Duration: 15-30 minutes Metabolized in the plasma by Hofmann elimination and
0.03 mg/kg ester hydrolysis
Continuous infusion: Duration not prolonged by renal or liver failure
1-3 mcg/kg/min
Rocuronium Intubating dose: Onset: 0.7-1.3 minutes Not associated with histamine release
0.45-1.2 mg/kg Duration: 22-67 minutes Used when succinylcholine is contraindicated or not preferred
Maintenance dose: Duration: 12-17 minutes Metabolized by liver; duration not significantly prolonged by 
0.075-0.15 mg/kg renal failure, but prolonged in patients with liver disease
Continuous infusion: No adverse cardiovascular effects
10-14 mcg/kg/min
7.2  Neuromuscular Blocking Agents (continued )
Agent Dose Onset/Duration Comments
Vecuronium Intubating dose: Onset: 2 minutes Not associated with histamine release
0.1-0.15 mg/kg Duration: 30-40 minutes Bile is the main route of elimination
Maintenance dose: Duration: 15-25 minutes Metabolized by liver; minimal reliance on renal function, 
0.01-0.15 mg/kg although active metabolite accumulates in real failure
Continuous infusion: Used when succinylcholine is contraindicated or not preferred
1 mcg/kg/min No adverse cardiovascular effects
Long-Acting
Doxacurium Intubating dose: Onset: 4-5 minutes No adverse cardiovascular effects
0.025-0.8 mg/kg Duration: 55-160 minutes Predominantly renally eliminated; significant accumulation in 
renal failure
Maintenance dose: Duration: 35-45 minutes
0.005-0.01 mg/kg
Continuous infusion:
0.25 mcg/kg/min (not
generally recommended)
Pancuronium Intubating dose: 0.06-0.1 mg/kg Onset: 2-3 minutes Tachycardia (vagolytic effect)
0.1 mg/kg Duration: 60-100 minutes Metabolized by liver; minimal reliance on renal function, 
Maintenance dose: Duration: 25-60 minutes although active metabolite accumulates in renal failure
0.01-0.015 mg/kg
Continuous infusion:
1 mcg/kg/min (not generally
recommended)
7.2  Neuromuscular Blocking Agents (continued )
Agent Dose Onset/Duration Comments
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7.3  Vasoactive Agents
Receptor Specificity Pharmacologic Effects
Agent and Dose  1 2 DM SM VD VC INT CHT Comments
Inotropes
Dobutamine Useful for acute management of low cardiac 
2-10 mcg/kg/min 1 3 2 — — 1 1 3 1 output states; in chronic CHF intermittent
10- 20 mcg/kg/min 2 4 3 — — 2 1 4 2 infusions palliate symptoms but do not 
prolong survival
Isoproterenol — 4 3 — — 3 — 4 4 Used primarily for temporizing treatment of
2-10 mcg/kg/min life-threatening bradycardia
Inamrinone Useful for acute management of low cardiac 
Loading dose: output states; can be combined with 
0.75 mg/kg dobutamine
Maintenance dose: Associated with the development of 
5-15 mcg/kg/min — — — — 2 2 — 3 3 thrombocytopenia
Milrinone Useful for acute management of low cardiac 
Loading dose: output states; can be combined with 
50 mcg/kg dobutamine
over 10 min
Maintenance dose:
0.375-0.75 — — — — 2 2 — 3 3
mcg/kg/min
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Mixed
Dopamine Doses 20-30 mcg/kg/min usually produce no 
2-5 mcg/kg/min — 3 — 4 — — — 2 1 added response; 2 mcg/kg/min may protect 
5-10 mcg/kg/min — 4 2 4 — — — 4 2 kidneys when giving other vasopressors
10-20 mcg/kg/min 3 4 1 — — — 3 3 3
Epinephrine Mixed vasoconstrictor/inotrope; stronger 
0.01-0.05 mcg/kg/min 1 4 2 — — 1 1 4 2 inotrope than norepinephrine; does not 
0.05 mcg/kg/min 4 3 1 — — — 3 3 3 constrict coronary or cerebral vessels; give
as needed to maintain BP
Vasopressors
Norepinephrine Mixed vasoconstrictor/inotrope; useful when 
2-20 mcg/min 4 2 — — — — 4 1 2 dopamine inadequate; give as needed to 
titrate to effect maintain BP (usually 20 mcg/min)
Phenylephrine Pure vasoconstrictor without direct cardiac 
Start at 30 mcg/min 4 — — — — — 4 — — effect; may cause reflex bradycardia; useful
IV and titrate when other pressors cause tachyarrhythmias;
give as much as needed to maintain BP
Vasopressin Pure vasoconstrictor without direct cardiac 
0.01-0.04 U/min — — — — — — 4 — — effect; may cause gut ischemia if dose is 
increased 0.04 U/min
7.3  Vasoactive Agents (continued )
Receptor Specificity Pharmacologic Effects
Agent and Dose  1 2 DM SM VD VC INT CHT Comments
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Vasodilators
Nitroglycerin Tachyphylaxis, headache
20-100 mcg/min — — — — 4 4 — — 1
AV
Nitroprusside — — — — 4 4 — — 1 Monitor thiocyanate levels if infusion duration 
0.5-10 mcg/kg/min AV 48 hours; maintain thiocyanate level 
10 mg/dL
Abbreviations: α1: α1-adrenergic; β1; β1-adrenergic; β2: β2-adrenergic; DM: dopaminergic; SM: smooth muscle; VD: vasodilator; VC: vasoconstrictor; INT:
inotropic; CHT: chronotropic. Vasoconstrictors usually are given by central vein and should be used only in conjunction with adequate volume repletion. All
can precipitate myocardial ischemia. All except phenylephrine can cause tachyarrhythmias.
Modified from: Gonzalez ER, Meyers DG. Assessment and management of cardiogenic shock. In Oronato JC, ed. Clinics in Emergency Medicine:
Cardiovascular Emergencies. New York, NY: Churchill Livingstone; 1986:125, with permission.
7.3  Vasoactive Agents (continued )
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7.4  Antiarrhythmic Agents
Agents Indications Dosage Comments
Class IA
Procainamide
Quinidine
Disopyramide
Ventricular ectopy; conversion of atrial 
fibrillation and atrial flutter; WPW
Ventricular ectopy; conversion of atrial 
fibrillation and atrial flutter; WPW
Ventricular ectopy; conversion of atrial 
fibrillation and atrial flutter; WPW
Loading dose: (IV) 15 mg/kg at 
25-50 mg/min
Maintenance dose: (IV) 2-5 mg/min 
Quinidine sulfate: 200-300 mg PO q6h
Quinidine sulfate: 324-648 mg PO q8h
100-300 mg PO q6h; SR: 100-300 mg 
PO q12h
N-acetyl procainamide is active metabolite; 
lupus-like syndrome; rash;
agranulocytosis; QT prolongation
Therapeutic range: PA 4-10 mg/L, NAPA 
10-20 mg/L
Diarrhea, nausea, headache dizziness; 
hypersensitivity reactions including
thrombocytopenia; hemolysis; fever
hepatitis; rash QT prolongation; increased
digoxin level
Dosage adjustment should be made when 
switching from one salt to another:
Quinidine sulfate (83% quinidine),
gluconate (62% quinidine),
polygalacturonate (60% quinidine)
Therapeutic range: 2.5-5 mg/L
Anticholinergic effects; negative inotropy; 
QT prolongation
Therapeutic range: 2-4 mg/L
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Class IB
Lidocaine
Mexiletine
Tocainide
7.4  Antiarrhythmic Agents (continued )
Agents Indications Dosage Comments
Malignant ventricular ectopy; WPW
Malignant ventricular ectopy
Malignant ventricular ectopy
1.5 mg/kg IV over 2 minutes, then
1-4 mg/min
150-300 mg PO q6-8h with food
200-600 mg PO q8h with food
No benefit in atrial arrhythmias
Seizures; paresthesias; delirium; levels
increased by cimetidine; minimal
hemodynamic effects
Therapeutic range: 1.5-5 mg/L
No benefit in atrial arrhythmias
Less effective than IA and IC agents
Nausea; tremor; dizziness; delirium; levels 
increased by cimetidine
Therapeutic range: 0.5-2 mg/L
No benefit in atrial arrhythmias
Less effective than IA and IC agents
Nausea; tremor; dizziness; delirium; 
agranulocytosis; pneumonitis; minimal
hemodynamic effects
Therapeutic range: 4-10 mg/L
187
Class IC
Flecainide
Propafenone
Class IB/IC (hybrid 
electrophysiologic
effects)
Moricizine
7.4  Antiarrhythmic Agents (continued )
Agents Indications Dosage Comments
Life-threatening ventricular arrhythmias
refractory to other agents
Prevention of symptomatic, disabling, 
paroxysmal supraventricular
arrhythmias, including atrial fibrillation
or flutter and WPW in patients without
structural heart disease
Life-threatening ventricular arrythmias 
refractory to other agents
SVT, WPW, and paroxysmal atrial 
fibrillation or flutter in patients without
structural heart disease
Life-threatening ventricular arrythmias 
refractory to other agents
100-200 mg PO q12h
150-300 mg PO q8h
100-300 mg PO q8h
Proarrhythmic effects; moderate negative 
inotropy; dizziness; conduction
abnormalities
Therapeutic range: 0.2-1 mg/L
Proarrhythmic effects; negative inotropy; 
dizziness; nausea; conduction
abnormalities
Proarrhythmic effects; dizziness; nausea; 
headache
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Class II (beta-
blocking agents)
Propranolol
Esmolol
Metoprolol
Class III
Amiodarone
7.4  Antiarrhythmic Agents (continued )
Agents Indications Dosage Comments
Slowing ventricular rate in atrial 
fibrillation, atrial flutter, and SVT;
suppression of PVCs
Slowing ventricular rate in atrial fibrillation,
atrial flutter, SVT, and MAT
Slowing ventricular rate in atrial 
fibrillation, atrial flutter, SVT, and MAT
Life-threatening ventricular arrhythmias, 
supraventricular arrhythmias, including
WPW refractory to other agents
Up to 0.5-1 mg IV, then 1-4 mg/h
(or 10-100 mg PO q6h)
Loading dose: 500 mcg/over 1 minute
Maintenance dose: 50 mcg/kg/min; 
rebolus and increase q5min by 50
mcg/kg/min to maximum of 400
Initial IV dose: 5 mg q5min up to 15 mg, 
then 25-100 mg PO q8-12h
800-1600 mg PO qd for 1-3 weeks, then 
600-800 mg PO qd for 4 weeks, then
100-400 mg PO qd
Not cardioselective; hypotension; 
bronchospasm; negative inotropy
Cardioselective at low doses; hypotension; 
negative inotropy; very short half-life
Cardioselective at low doses; hypotension; 
negative inotropy
Half-life 50 days; pulmonary fibrosis; 
corneal microdeposits; hypo/
hyperthyroidism; bluish skin; hepatitis;
photosensitivity; conduction abnormalities;
mild negative inotropy; increased effect of
coumadin; increased digoxin level
Therapeutic range: 1-2.5 mg/L
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Bretylium
Sotalol
Dofetilide
Class IV (calcium 
channel
antagonists)
Verapamil
Diltiazem
7.4  Antiarrhythmic Agents (continued )
Agents Indications Dosage Comments
Refractory ventricular tachycardia
and ventricular fibrillation
Life-threatening ventricular arrythmias
Conversion of atrial fibrillation
Conversion of SVT; slowing ventricular 
rate in atrial fibrillation, atrial flutter, 
and MAT
Conversion of SVT; slowing ventricular 
rate in atrial fibrillation, atrial flutter, 
and MAT
5-10 mg/kg IV boluses q10 min up to 
30 mg/kg, then 0.5-2 mg/min
80-160 mg PO q12h; may increase up to 
160 mg PO q8h
250-500 mcg orally twice a day
IV bolus: 5-10 mg over 2-3 minutes
(repeat in 30 min prn), continuous
infusion: 2.5-5 mcg/kg/min
PO: 40-160 mg PO q8h
IV bolus: 0.25 mg/kg over 2 minutes 
(repeatin 15 minutes prn with 0.35 mg/kg
IV); Maintenance infusion: 5-15 mg/h
PO: 30-90 mg PO q6h
Initial hypertension, then postural 
hypotension; nausea and vomiting;
parotitis; catecholamine sensitivity
Beta-blocker with class III properties; 
proarrhythmic effects; QT prolongation
Dose adjusted based on QTc interval and 
creatinine clearance
Hypotension; negative inotropy; conduction 
disturbances; increased digoxin level;
generally contraindicated in WPW
Hypotension; less negative inotropy than 
verapamil; conduction disturbances; rare
hepatic injury; generally contraindicated in
WPW
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Miscellaneous
agents
Adenosine
Atropine
Digitalis
Abbreviations: AV, atrioventricular; MAT, multifocal atrial tachycardia; SR: sustained release; SVT, supraventricular tachycardia; WPW, Wolff-Parkinson-White.
7.4  Antiarrhythmic Agents (continued )
Agents Indications Dosage Comments
Conversion of SVT, including WPW
Initial therapy for symptomatic 
bradycardia
Slowing AV conduction in atrial 
fibrillation and atrial flutter
6-mg rapid IV bolus; if ineffective, 
12-mg rapid IV bolus 2 minutes later;
follow bolus with fast flush; use smaller
doses if giving through central venous
line
0.5-mg IV bolus; repeat q5min prn to 
total of 2 mg IV
Loading dose: 0.5 mg IV, then 0.25 mg IV
q4-6h up to 1 mg; Maintenance dose:
0.125-0.375 mg PO/IV qd
Flushing; dyspnea; nodal blocking effect 
increased by dipyridamole and decreased
by theophylline and caffeine; very short
half-life (10 seconds)
May induce tachycardia and ischemia
Heart block; arrhythmias; nausea; yellow 
vision; numerous drug interactions,
generally contraindicated in WPW
Therapeutic range: 0.5-2.0 mg/mL
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7.5  Therapeutic Drug Monitoring
Drug Usual Therapeutic Range Usual Sampling Time
Antibiotics
Amikacin Peak: 20-40 mg/L Peak: 30-60 minutes after a 30-minute infusion
Trough: 10 mg/L Trough: Just before next dose
Chloramphenicol Peak: 10-25 mg/L Peak: 30-90 minutes after a 30-minute infusion
Trough: 5-10 mg/L Trough: Just before the next dose
Flucytosine Peak: 50-100 mg/L Peak: 1-2 hours after an oral dose
Trough: 25 mg/L Trough: Just before the next dose
Gentamicin Peak: 4-10 mg/L Peak: 30-60 minutes after a 30-minute infusion
Trough: 2 mg/L Trough: Just before the next dose
Tobramycin Peak: 4-10 mg/L Peak: 30-60 minutes after a 30-minutes infusion
Trough: 2 mg/L Trough: Just before the next dose
Netilmicin Peak: 4-10 mg/L Peak: 30-60 minutes after a 30-minutes infusion
Trough: 2 mg/L Trough: Just before the next dose
Vancomycin Peak: 20-40 mg/L Peak: 1 hour after end of a 1-hour infusion
Trough: 20 mg/L Trough: Just before the next dose
Sulfonamides Peak: 100-150 mg/L Peak: 2 hours after 1-hour infusion
(sulfamethoxazole, Trough: Not applicable
sulfadiazine, cotrimoxazole)
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Antiarrhythmics
Amiodarone 0.5-2 mg/L Trough: Just before next dose
Digoxin 0.5-2 mcg/L Peak: 8-12 hours after administered dose
Trough: Just before next dose
Disopyramide 2-4 mg/L Trough: Just before next dose
Flecainide 0.2-1.0 mg/L Trough: Just before next dose
Lidocaine 1.5-5 mg/L Anytime during a continuous infusion
Mexiletine 0.5-2 mg/L Trough: Just before next dose
Procainamide/NAPA Procainamide: 4-10 mg/L IV: Immediately after IV loading dose: anytime during continuous infusion
NAPA: 10-20 mg/L
Quinidine 2.5-5 mg/L Trough: Just before next dose
Tocainide 4-10 mg/L Trough: Just before next dose
Anticonvulsants
Carbamazepine 4-12 mg/L Trough: Just before next dose
Pentobarbital 20-50 mcg/L IV: Immediately after IV loading dose: anytime during continuous infusion
Phenobarbital 15-40 mg/L Trough: Just before next dose
Phenytoin 10-20 mg/L IV: 2-4 hours after dose
Trough: PO/IV: Just before next dose
Free phenytoin level: 1-2 mg/L
Valproic acid 50-100 mg/L Trough: Just before next dose
7.5  Therapeutic Drug Monitoring (continued )
Drug Usual Therapeutic Range Usual Sampling Time
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Bronchodilators
Theophylline 10-20 mg/L IV: Prior to IV bolus dose, 30 minutes after end of bolus dose, anytime during
continuous infusion
PO: peak: 2 hours after rapid-release product, 4 hours after sustained-
release product
Trough: Just before next dose
Miscellaneous
Cyclosporine 50-150 ng/mL (whole blood, HPLC) Trough: IV, PO: Just before next dose
7.5  Therapeutic Drug Monitoring (continued )
Drug Usual Therapeutic Range Usual Sampling Time
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7.6  Tips for Calculating IV Medication Infusion Rates
Information Required to Calculate IV Infusion Rates to Deliver Specific Medication Doses
• Dose to be infused (eg, mg/kg/min, mg/min, mg/h)
• Concentration of IV solution (eg, dopamine 400 mg in D5W 250 mL  1.6 mg/mL; nitroglycerin 50 mg in D5W 250 mL  200 mcg/mL)
• Patient’s weight
1. Calculate the IV infusion rate in milliliters per hour for a 70-kg patient requiring dobutamine 5 mcg/kg/min using a dobutamine admixture of 500 mg in
D5W 250 mL.
• Dose to be infused: 5 mcg/kg/min
• Dobutamine concentration: 500 mg/250 mL  2 mg/mL or 2000 mcg/mL
• Patient weight: 70 kg
Calculation:
5 mcg/kg/min  70 kg  350 mcg/min 
350 mcg/min  60 min/h  21,000 mcg/h 
21,000 mcg/h  2000 mcg/mL  10.5 mL/h
Answer: Setting the infusion pump at 10.5 mL/h will deliver dobutamine at a dose of 5 mcg/kg/min.
2. Calculate the IV infusion rate in milliliters per hour for a 70-kg patient requiring nitroglycerin 50 mcg/min using a nitroglycerin admixture of 50 mg in
D5W 250 mL.
• Dose to be infused: 50 mcg/min
• Nitroglycerin concentration: 50 mg/250 mL  0.2 mg/mL or 200 mcg/mL
• Patient weight: 70 kg
Calculation:
50 mcg/min  60 min/h  3000 mcg/h
3000 mcg/h  200 mcg/mL  15 mL/h
Answer: Setting the infusion pump at 15 mL/h will deliver nitroglycerin at a dose of 50 mcg/min.
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3. Calculate the IV loading dose and infusion rate in milliliters per hour for a 70-kg patient requiring aminoph-ylline 0.6 mg/kg/h using an aminophylline
admixture of 1 g in D5W 500 mL. The loading dose should be diluted in D5W 100 mL and infused over 30 minutes.
• Desired dose: Loading dose: 6 mg/kg Maintenance infusion: 0.6 mg/kg/h
• Aminophylline concentration: Aminophylline vial: 500 mg/20 mL  25 mg/mL Aminophylline infusion: 1 g/500 mL  2 mg/mL
• Patient weight: 70 kg
Calculation:
Loading dose: 6 mg/kg 3 70 kg  420 mg
420 mg  25 mg/mL  16.8 mL
Infusion rate: Aminophylline 16.8 mL  D5W 100 mL  116.8 mL
116.8 mL  0.5/h  233.6 mL/h
Answer: Setting the infusion pump at 234 mL/h will infuse the aminophylline loading dose over 1/2 hour
Maintenance dose: 0.6 mg/kg/h  70 kg  42 mg/h
42 mg/h  2 mg/mL  21 mL/h
Answer: Setting the infusion pump at 21 mL/h will deliver the aminophylline maintenance dose at 42 mg/h, or 0.6 mg/kg/h.
7.6  Tips for Calculating Intravenous Medication Infusion Rates (continued )
